## UNITED STATES DISTRICT COURT EASTERN DISTRICT OF WISCONSIN

## UNITED STATES OF AMERICA, and THE STATE OF WISCONSIN, ex rel. DR. TOBY TYLER WATSON,

Plaintiffs,

v.

JENNIFER KING VASSEL,

Defendant.

### AFFIDAVIT OF BRADLEY S. FOLEY IN SUPPORT OF DEFENDANT JENNIFER KING VASSEL'S MOTION IN LIMINE TO PRECLUDE REFERENCE TO GEODON PRESCRIPTIONS

Case No. 11-CV-236

STATE OF WISCONSIN

COUNTY OF MILWAUKEE

BRADLEY S. FOLEY, being duly sworn under oath, deposes and states as follows:

1. I am one of the attorneys representing defendant Jennifer King Vassel in the above-

referenced action and am authorized to make this affidavit on her behalf.

) ) ss.

)

2. Attached as Exhibit A is a true and accurate copy of the supplement to the plaintiff's

initial disclosures.

3. Attached as <u>Exhibit B</u> is a true and accurate copy of the October 30, 2013 letter from

the State acknowledging the records request.

4. Attached as <u>Exhibit C</u> is a true and accurate copy of the November 25, 2013 letter

from the State providing the requested information.

5. Attached as <u>Exhibit D</u> is a true and accurate copy of the American Hospital

### Case 2:11-cv-00236-JPS Filed 11/26/13 Page 1 of 2 Document 171

Formulary Service, 2005 edition, information for ziprasidone.

6. Attached as <u>Exhibit E</u> is a true and accurate copy of the United States Pharmacopeia

Drug Information (USP DI), 2005 edition, information for ziprasidone.

7. Attached as Exhibit F is a true and accurate copy of the Physicians' Desk Reference,

2005 edition, information for ziprasidone.

s/Bradley S. Foley Bradley S. Foley

Subscribed and sworn to before me this 26th day of November, 2013.

s/Carrie Wentland Notary Public, State of Wisconsin My Commission expires: <u>1/19/14</u>

### IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF WISCONSIN MILWAUKEE DIVISION

# UNITED STATES OF AMERICA, and The STATE OF WISCONSIN,

Ex rel. Dr. Toby Tyler Watson,

Plaintiff,

V.

JENNIFER KING-VASSEL, CAPS CHILD & ADOLESCENT PSYCHIATRIC SERVICES, AND ENCOMPASS EFFECTIVE MENTAL HEALTH SERVICES, INC.. Civil Action No.: 11-C-0236

### FALSE CLAIMS ACT MEDICAID FRAUD

### JURY TRIAL DEMANDED

Defendants.

## SUPPLEMENT TO RELATOR'S INITIAL DISCLOSURES

Pursuant to Fed. R. Civ. P. 26, Relator-plaintiff Dr. Toby Tyler Watson hereby serves these Supplemental Initial Disclosures to Defendant King-Vassel. Relator has discovered documents from Walmart Pharmacy, not listed in Relator's Initial Disclosures, that were produced to Relator in response to a records request that was submitted after Initial Disclosures were exchanged. These documents may be relevant to disputed facts alleged with particularity in the pleadings, and to damages calculations.

These disclosures do not constitute waiver of any work product protection and are without prejudice to any other issue or argument. Relator reserves the right to supplement disclosures as additional discovery is undertaken.

Dated: September 4, 2013

Relator Dr. Toby Tyler Watson, by

<u>/s/ Rebecca L. Gietman</u> Rebecca L. Gietman 805 S. Madison St. Chilton, WI 53014 414-841-7173



### DIVISION OF HEALTH CARE ACCESS AND ACCOUNTABILITY



1 WEST WILSON STREET P O BOX 309 MADISON WI 53701-0309

Telephone: 608-266-8922 FAX: 608-266-1096 TTY: 711 or 800-947-3529 dhs.wisconsin.gov

Scott Walker Governor

Kitty Rhoades Secretary State of Wisconsin Department of Health Services

October 30, 2013

Bradley S. Foley, Attorney Gutglass Erickson Bonville & Larson, S.C. 735 N Water Street Suite 1400 Milwaukee WI 53202-4267

bradley.foley@gebsc.com

Dear Mr. Foley:

This letter is to acknowledge your open records request (your file number 911.19) to the Department of Health Services (DHS), Division of Health Care Access & Accountability (DHCAA) regarding certified copies of the Medicaid formulary for prescription medications Clonidine, Risperdal, Zoloft, Seroquel and Prozac for 2007 and 2008.

Under the provisions of Wis. Stat. §19.35(3), the Department can charge for locating records if the cost is \$50.00 or more, as well as the costs of copies and mailing/shipping the records responsive to the request.

At this time, the Department is assessing the effort, time and costs to locate, retrieve and deliver the requested records to you and will provide you with that information as soon as is practicable.

You may contact me with any questions concerning this request at 608-267-6847 or tricia.laplant@wi.gov.

Sincerely,

aplant ricia d

Tricia Laplant, Deputy Director Bureau of Operational Coordination DHCAA

cc: Cheryl Jatczak, Bureau Director Phillip Rangsuebsin, Office of Legal Counsel Rita Subhedar, Bureau of Benefits Management

Ref: CCT #2259

	EXHIBIT	
tabbles"	B	
-		

Wisconsin.gov

Case 2:11-cv-00236-JPS Filed 11/26/13 Page 1 of 1 Document 171-2

DIVISION OF HEALTH CARE ACCESS AND ACCOUNTABILITY



1 WEST WILSON STREET P O BOX 309 MADISON WI 53701-0309

Telephone: 608-266-8922 FAX: 608-266-1096 TTY: 711 or 800-947-3529 dhs.wisconsin.gov

Scott Walker Governor

Kitty Rhoades Secretary State of Wisconsin Department of Health Services

November 25, 2013

Bradley S. Foley, Attorney Gutglass Erickson Bonville & Larson, S.C. 735 N Water Street Suite 1400 Milwaukee WI 53202-4267

bradley.foley@gebsc.com

Dear Mr. Foley:

This letter is to provide you with the records responsive to your open records request (your file number 911.19) to the Department of Health Services (DHS), Division of Health Care Access & Accountability (DHCAA) regarding the Medicaid formulary for prescription medications Clonidine, Risperdal, Zoloft, Seroquel and Prozac for 2007 and 2008.

Attached is a report of the records you requested. This is being provided to you at a cost of \$150.60 per your prepayment.

This fulfills your open records request and the Department now considers your request closed. If you should have any questions, you may contact me at 608-267-6847 or <u>tricia.laplant@wi.gov.</u>

Sincerely,

plant

Tricia Laplant, Deputy Director Bureau of Operational Coordination DHCAA

cc: Cheryl Jatczak, Bureau Director Phillip Rangsuebsin, Office of Legal Counsel Rita Subhedar, Bureau of Benefits Management

Ref: CCT #2259



Wisconsin.gov

### DATA DICTIONARY

Field	Description
List Provides	Products selected based on coverage available between 1/1/2007-12/31/2008.
	Products available based on manufacturers having a signed federal rebate agreement with the
	Center for Medicare and Medicaid (CMS) and are not considered less-than-effective, as
	determined by the Food and Drug Administration.
	First Databank is the drug clearinghouse used by Wisconsin Medicaid.
	Unique code assigned by the Food And Drug Administration. Identifies the manufacturer, the
National Drug Code	product ingredient/route/dosage form, and the package size.
Label Name	Product name as described on the packaging.
Covered Service Start Date	The first day the National Drug Code was available as a covered service.
Covered Service End Date	The last day the National Drug Code was available as a covered service.
	Preferred Drug List (PDL) values: Y = Preferred Status or N = Non Preferred Status. Null values
PDL Status	identify no PDL status.
	The first day the National Drug Code had an active Preferred Drug List status. Null values identify
PDL Status Start Date	no PDL status.
	The last day the National Drug Code had an active Preferred Drug List status. Null values identify
PDL Status End Date	no PDL status.
	The first day the National Drug Code required Brand Medically Necessary Prior Authorization
BMN PA Required Start Date	(BMN PA). Null values identify BMN PA did not apply.
	The last day the National Drug Code required Brand Medically Necessary Prior Authorization. Null
BMN PA Required End Date	values identify BMN PA did not apply.
	The first day the National Drug Code had a State Maximum Allowed Cost (SMAC) rate applied.
SMAC Rate Start Date	Null values identify SMAC rate was not available for the National Drug Code.
	The last day the National Drug Code had a State Maximum Allowed Cost (SMAC) rate applied.
SMAC Rate End Date	Null values identify SMAC rate was not available for the National Drug Code.
	Identifies if there were any diagnosis restrictions applied to the National Drug Code. Values: Y =
Diagnosis Restriction	Yes or N = No.
	Identifies if there was a clinical prior authorization required for the National Drug Code. Values: Y
<b>Clinical Prior Authorization</b>	= Yes or N = No.

National Drug Code	Label Name	Covered Service Start Date	Covered Service End Date	PDL Status	PDL Status Start Date	PDL Status End Date	BMN PA Required Start Date	BMN PA Required End Date	SMAC Rate Start Date	SMAC Rate End Date		Clinical Prior Authorization
00002300475	PROZAC WEEKLY 90 MG CAPSULE	1/1/2007	12/31/2008	N	1/1/2007	12/31/2008					N	N
00049490030	ZOLOFT 50 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	2/28/2007	3/1/2007	12/31/2008	3/1/2007	12/31/2008	N	N
00049490041	ZOLOFT 50 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	2/28/2007	3/1/2007	12/31/2008	3/1/2007	12/31/2008	N	N
00049490066	ZOLOFT 50 MG TABLET	1/1/2007	10/9/2008	Y	1/1/2007	2/28/2007	3/1/2007	12/31/2008	3/1/2007	12/31/2008	N	N
00049490073	ZOLOFT 50 MG TABLET	1/1/2007	10/9/2008	Y	1/1/2007	2/28/2007	3/1/2007	12/31/2008	3/1/2007	12/31/2008	N	N
00049490094	ZOLOFT 50 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	2/28/2007	3/1/2007	12/31/2008	3/1/2007	12/31/2008	N	N
00049491030	ZOLOFT 100 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	2/28/2007	3/1/2007	12/31/2008	3/1/2007	12/31/2008	N	N
00049491041	ZOLOFT 100 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	2/28/2007	3/1/2007	12/31/2008	3/1/2007	12/31/2008	N	N
00049491066	ZOLOFT 100 MG TABLET	1/1/2007	10/9/2008	Y	1/1/2007	2/28/2007	3/1/2007	12/31/2008	3/1/2007	12/31/2008	N	N
00049491073	ZOLOFT 100 MG TABLET	1/1/2007	10/9/2008	Y	1/1/2007	2/28/2007	3/1/2007	12/31/2008	3/1/2007	12/31/2008	N	N
00049491094	ZOLOFT 100 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	2/28/2007	3/1/2007	12/31/2008	3/1/2007	12/31/2008	N	N
00049494023	ZOLOFT 20 MG/ML ORAL CONC	1/1/2007	12/31/2008	Y	1/1/2007	2/28/2007	4/1/2007	12/31/2008	4/1/2007	11/30/2007	N	N
00049496030	ZOLOFT 25 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	2/28/2007	3/1/2007	12/31/2008	3/1/2007	12/31/2008	N	N
00049496050	ZOLOFT 25 MG TABLET	1/1/2007	5/31/2007	Y	1/1/2007	2/28/2007	3/1/2007	12/31/2008	3/1/2007	12/31/2008	N	N
00228212710	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00228212750	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00228212810	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00228212850	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00228212910	CLONIDINE HCL 0.3 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00310027110	SEROQUEL 100 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	12/31/2008					N	N
00310027139	SEROQUEL 100 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	12/31/2008					N	N
00310027210	SEROQUEL 200 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	12/31/2008					N	N
00310027239	SEROQUEL 200 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	12/31/2008					N	N
00310027439	SEROQUEL 300 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	12/31/2008					N	N
00310027460	SEROQUEL 300 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	12/31/2008					N	N
00310027510	SEROQUEL 25 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	12/31/2008					N	N
00310027534	SEROQUEL 25 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	12/31/2008					N	N
00310027539	SEROQUEL 25 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	12/31/2008					N	N
00310027810	SEROQUEL 50 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	12/31/2008					N	N
00310027834	SEROQUEL 50 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	12/31/2008					N	N
00310027839	SEROQUEL 50 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	12/31/2008					N	N
00310027910	SEROQUEL 400 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	12/31/2008					N	N
00310027939	SEROQUEL 400 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	12/31/2008					N	N
00310028239	SEROQUEL XR 200 MG TABLET	7/1/2007	12/31/2008	N	8/1/2007	12/31/2008					N	N
00310028255	SEROQUEL XR 200 MG TABLET	7/1/2007	12/31/2008	N	8/1/2007	12/31/2008					N	N
00310028260	SEROQUEL XR 200 MG TABLET	7/1/2007	12/31/2008	N	8/1/2007	12/31/2008					N	N
00310028339	SEROQUEL XR 300 MG TABLET	7/1/2007	12/31/2008	N	8/1/2007	12/31/2008					N	N
00310028355	SEROQUEL XR 300 MG TABLET	7/1/2007	12/31/2008	N	8/1/2007	12/31/2008					N	N

National Drug Code	Label Name	Covered Service Start	Covered Service End	PDL Status	PDL Status Start Date	PDL Status End Date	BMN PA Required Start	BMN PA Required End	SMAC Rate Start Date	The of the second secon	and the second	Clinical Prior Authorization
00040000000		Date	Date	N	0/4/0007	40/24/0000	Date	Date				TELEVISION
00310028360	SEROQUEL XR 300 MG TABLET	7/1/2007	12/31/2008	N	8/1/2007	12/31/2008					N	N
00310028439	SEROQUEL XR 400 MG TABLET	7/1/2007	12/31/2008	N	8/1/2007	12/31/2008					N	N
00310028455	SEROQUEL XR 400 MG TABLET	7/1/2007	12/31/2008	N	8/1/2007	12/31/2008					N	N
00310028460	SEROQUEL XR 400 MG TABLET	7/1/2007	12/31/2008	N	8/1/2007	12/31/2008				1010110000	N	N
00378015201	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008					·	1/1/2007	12/31/2008	N	N
00378015210	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00378018601	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00378018610	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00378019901	CLONIDINE HCL 0.3 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00603295721	CLONIDINE HCL 0.1 MG TABLET	4/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00603295728	CLONIDINE HCL 0.1 MG TABLET	4/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00603295732	CLONIDINE HCL 0.1 MG TABLET	4/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00603295821	CLONIDINE HCL 0.2 MG TABLET	4/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00603295828	CLONIDINE HCL 0.2 MG TABLET	4/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00603295832	CLONIDINE HCL 0.2 MG TABLET	4/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00603295921	CLONIDINE HCL 0.3 MG TABLET	4/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00603295928	CLONIDINE HCL 0.3 MG TABLET	4/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00615257263	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	8/7/2007						1/1/2007	12/31/2008	N	N
00615257363	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	8/7/2007						1/1/2007	12/31/2008	N	N
00677192201	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00677192210	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00677192301	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008	1					1/1/2007	12/31/2008	N	N
00677192310	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008	1					1/1/2007	12/31/2008	N	N
00677192401	CLONIDINE HCL 0.3 MG TABLET	1/1/2007	4/5/2007						1/1/2007	12/31/2008	N	N
00777310402	PROZAC 10 MG PULVULE	1/1/2007	12/31/2008	1			1/1/2007	12/31/2008	1/1/2007	12/31/2008	N	N
00777310407	PROZAC 10 MG PULVULE	1/1/2007	8/7/2007				1/1/2007	12/31/2008	1/1/2007	12/31/2008	N	N
00777310502	PROZAC 20 MG PULVULE	1/1/2007	12/31/2008				1/1/2007	12/31/2008	1/1/2007	12/31/2008	N	N
00777310507	PROZAC 20 MG PULVULE	1/1/2007	12/31/2008				1/1/2007	12/31/2008	1/1/2007	12/31/2008	N	N
00777310530	PROZAC 20 MG PULVULE	1/1/2007	12/31/2008				1/1/2007	12/31/2008	1/1/2007	12/31/2008	N	N
00777310730	PROZAC 40 MG PULVULE	1/1/2007	12/31/2008	-			1/1/2007	12/31/2008	1/1/2007	12/31/2008	N	N
00777512058	PROZAC 20 MG/5 ML SOLUTION	1/1/2007	12/31/2008		1		1/1/2007	12/31/2008	1/1/2007	12/31/2008	N	N
00904102661	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	8/7/2007	-				12.0112000	1/1/2007	12/31/2008	N	N
00904102761	CLONIDINE HCL 0.3 MG TABLET	1/1/2007	8/7/2007						1/1/2007	12/31/2008	N	N
00904565661	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008	-					1/1/2007	12/31/2008	N	N
00904565761	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
00904565861	CLONIDINE HCL 0.3 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
50458030001	RISPERDAL 1 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008	11/1/2008	12/31/2008	8/1/2008	12/31/2008	N	N
50458030006	RISPERDAL 1 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008	11/1/2008	12/31/2008	8/1/2008	12/31/2008	N	N
50458030006		1/1/2007		Y	1/1/2007	7/31/2008						
50456030050	RISPERDAL 1 MG TABLET	1/1/2007	12/31/2008	I T	1/1/2007	1131/2008	11/1/2008	12/31/2008	8/1/2008	12/31/2008	N	N

National Drug Code	Label Name	Covered	Covered	PDL	PDL Status Start	PDL Status	BMN PA	BMN PA	SMAC Rate	a second degree in the second	Contraction of the second	Clinical Prior
		Service Start Date	Service End Date	Status	Date	End Date	Required Start Date	Required End Date	Start Date	End Date	Restriction	Authorization
50458030101	RISPERDAL 0.25 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008	11/1/2008	12/31/2008	8/1/2008	12/31/2008	N	N
50458030104	RISPERDAL 0.25 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008	11/1/2008	12/31/2008	8/1/2008	12/31/2008	N	N
50458030150	RISPERDAL 0.25 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008	11/1/2008	12/31/2008	8/1/2008	12/31/2008	N	N
50458030201	RISPERDAL 0.5 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008	11/1/2008	12/31/2008	8/1/2008	12/31/2008	N	N
50458030206	RISPERDAL 0.5 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008	11/1/2008	12/31/2008	8/1/2008	12/31/2008	N	N
50458030250	RISPERDAL 0.5 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008	11/1/2008	12/31/2008	8/1/2008	12/31/2008	N	N
50458030503	RISPERDAL 1 MG/ML SOLUTION	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008	11/1/2008	12/31/2008	8/1/2008	12/31/2008	N	N
50458030611	RISPERDAL CONSTA 25 MG SYR	1/1/2007	12/31/2008								N	N
50458030711	RISPERDAL CONSTA 37.5 MG SYR	1/1/2007	12/31/2008								N	N
50458030811	RISPERDAL CONSTA 50 MG SYR	1/1/2007	12/31/2008								N	N
50458030911	RISPERDAL CONSTA 12.5 MG SYR	4/24/2007	12/31/2008								N	N
50458031528	RISPERDAL M-TAB 1 MG ODT	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008					N	N
50458031530	RISPERDAL M-TAB 1 MG ODT	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008					N	N
50458032001	RISPERDAL 2 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008	11/1/2008	12/31/2008	8/1/2008	12/31/2008	N	N
50458032006	RISPERDAL 2 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008	11/1/2008	12/31/2008	8/1/2008	12/31/2008	N	N
50458032050	RISPERDAL 2 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008	11/1/2008	12/31/2008	8/1/2008	12/31/2008	N	N
50458032528	RISPERDAL M-TAB 2 MG ODT	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008					N	N
50458033001	RISPERDAL 3 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008	11/1/2008	12/31/2008	8/1/2008	12/31/2008	N	N
50458033006	RISPERDAL 3 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008	11/1/2008	12/31/2008	8/1/2008	12/31/2008	N	N
50458033050	RISPERDAL 3 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008	11/1/2008	12/31/2008	8/1/2008	12/31/2008	N	N
50458033528	RISPERDAL M-TAB 3 MG ODT	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008					N	N
50458035001	RISPERDAL 4 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008	11/1/2008	12/31/2008	8/1/2008	12/31/2008	N	N
50458035006	RISPERDAL 4 MG TABLET	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008	11/1/2008	12/31/2008	8/1/2008	12/31/2008	N	N
50458035528	RISPERDAL M-TAB 4 MG ODT	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008					N	N
50458039528	RISPERDAL M-TAB 0.5 MG ODT	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008					N	N
50458039530	RISPERDAL M-TAB 0.5 MG ODT	1/1/2007	12/31/2008	Y	1/1/2007	7/31/2008					N	N
51079029901	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
51079029917	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
51079029919	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
51079029920	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
51079029962	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
51079029963	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
51079030001	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
51079030017	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
51079030019	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
51079030020	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
51079030030	CLONIDINE HCL 0.2 MG TABLET	4/1/2008	12/31/2008						1/1/2007	12/31/2008	N	N
51079030056	CLONIDINE HCL 0.2 MG TABLET	4/1/2008	12/31/2008						1/1/2007	12/31/2008	N	N
51079030062	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N

National Drug Code	Label Name	Covered	Covered	PDL	PDL Status Start		BMN PA	BMN PA	SMAC Rate		Contraction Contraction	Clinical Prior
地理会会の経		Service Start Date	Service End Date	Status	Date	End Date	Required Start Date	Required End Date	Start Date	End Date	Restriction	Authorization
51079030063	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008				Sector .	COLUMN STREET	1/1/2007	12/31/2008	N	N
51079030101	CLONIDINE HCL 0.3 MG TABLET	7/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
51079030120	CLONIDINE HCL 0.3 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
51079030162	CLONIDINE HCL 0.3 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
51079030163	CLONIDINE HCL 0.3 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
51552048001	CLONIDINE HCL POWDER	1/1/2007	12/31/2008								N	N
51552048002	CLONIDINE HCL POWDER	1/1/2007	12/31/2008								N	N
53489021501	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
53489021510	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
53489021601	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
53489021610	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
53489021701	CLONIDINE HCL 0.3 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
54738090701	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	6/30/2007						1/1/2007	12/31/2008	N	N
54738090703	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	6/30/2007						1/1/2007	12/31/2008	N	N
54738090801	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	6/30/2007						1/1/2007	12/31/2008	N	N
54738090803	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	6/30/2007						1/1/2007	12/31/2008	N	N
54738090901	CLONIDINE HCL 0.3 MG TABLET	1/1/2007	6/30/2007						1/1/2007	12/31/2008	N	N
62584033901	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
62584033911	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
62584033933	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	8/7/2007						1/1/2007	12/31/2008	N	N
62584065701	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
62584065711	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
62584065733	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	8/7/2007						1/1/2007	12/31/2008	N	N
62584065901	CLONIDINE HCL 0.3 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
62584065911	CLONIDINE HCL 0.3 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
63739006001	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	8/7/2007						1/1/2007	12/31/2008	N	N
63739006002	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	8/7/2007						1/1/2007	12/31/2008	N	N
63739006003	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	8/7/2007						1/1/2007	12/31/2008	N	N
63739006010	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
63739006015	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
63739006101	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	8/7/2007						1/1/2007	12/31/2008	N	N
63739006102	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	8/7/2007						1/1/2007	12/31/2008	N	N
63739006103	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	8/7/2007	1					1/1/2007	12/31/2008	N	N
63739006110	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
63739006115	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
63739006210	CLONIDINE HCL 0.3 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
63739006215	CLONIDINE HCL 0.3 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
67253026310	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
67253026311	CLONIDINE HCL 0.1 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N

National Drug Code	Label Name	Covered	Covered	PDL	PDL Status Start	PDL Status	BMN PA	BMN PA	SMAC Rate	SMAC Rate	Diagnosis	Clinical Prior
<b>有些时间的</b> 有一个	目前に同時になると言語でも言語	Service Start	Service End	Status	Date	End Date	Required Start	1.000064310010511=0003	Start Date	End Date	Restriction	Authorization
		Date	Date				Date	Date				e to be the first of
67253026410	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
67253026411	CLONIDINE HCL 0.2 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N
67253026510	CLONIDINE HCL 0.3 MG TABLET	1/1/2007	12/31/2008						1/1/2007	12/31/2008	N	N

antipsychotic agents and may involve antagonism of central type 2 serotonergic (5-HT<sub>2</sub>) receptors and central dopamine D, receptors.

SumMon" (see Users Guide). For additional information on this drug until a more detailed monograph is developed and published, the manufacturer's labeling should be consulted. It is essential that the labeling be consulted for detailed information on the usual cautions, precautions, and contraindications concerning potential drug interactions and/or laboratory test interferences and for information on acute toxicity.

### preparations

t

d

у le

le 3

C-

гу

1d

ne

he

13

:c-

nts

stic

an

1gs

too

ical

iso-

tely

uld

s în

rec-

fetal

a in

mes

s. In

3 the

g/m<sup>2</sup>

n the

ly in

) and

sper-

sage

or, as

\_4 of

jams.

s, one

posed

apy is

poten-

me on

ut not

es the

peared

gment

terone

human

artially

)-effect

me, are

eridone

s chemes some

ias been

:ts differ

he exact

ucidated

ost other

Risperidone			
Oral		1.1.1	
Solution	1 mg/mL		Risperdal*, Janssen
Tablets	0.25 mg		Risperdal <sup>®</sup> (with propylene glycol; scored), Janssen
	0.5 mg		Risperdal <sup>®</sup> (with propylene glycol; scored), Janssen
	1 mg	5	Risperdal® (with propylene glycol; scored), Janssen
	2 mg		Risperdal* (with propylene glycol; scored), Janssen
5. T - 4	3 mg	- 1 M.	Risperdal <sup>®</sup> (with propylene glycol; scored), Janssen
10	4 mg		Risperdal <sup>®</sup> (with propylene glycol; scored), Janssen
Tablets, orally disintegrating	0.5 mg		Risperdal <sup>®</sup> M-TAB <sup>®</sup> (with aspartame), Janssen
	1 mg	1.30	Risperdal <sup>®</sup> M-TAB <sup>®</sup> (with aspartame), Janssen
	2 mg	2-10	Risperdal <sup>®</sup> M-TAB <sup>®</sup> (with aspartame), Janssen
21111		i ruite	<ul> <li>Referred and the second se second second sec</li></ul>

fUse is not currently included in the labeling approved by the US Food and Drug Administration Selected Revisions January 2005, © Copyright, May 1994, American Society of Health-System Pharmacists, Inc

#### Ziprasidone

Ziprasidone has been referred to as an atypical antipsychotic agent.

#### Uses

 Psychotic Disorders Schizophrenia Ziprasidone is used for the symptomatic management of schizophrenia. Because of ziprasidone's greater capacity to prolong the QT/QTe-interval compared with that of several other antipsychotic agents, use of ziprasidone may be reserved for patients whose disease fails to respond adequately to appropriate courses of other antipsychotic agents. (See Prolongation of QT interval under Warnings/Precautions: Warnings, in Cautions.) However, it should be noted that patients with a history of resistance to antipsychotic therapy (i.e., failed to respond to adequate courses of 2 or more antipsychotic agents) usually were excluded in clinical studies of ziprasidone.

ing and reaching one

Efficacy of oral ziprasidone was evaluated in 5 placebo-controlled studies of variable duration (4 short-term [4-6 weeks] and one long-term [52 weeks]), principally in patients with schizophrenic disorders in hospital settings. Ziprasidone appears to be superior to placebo in improving both positive and negative manifestations in acute exacerbations of schizophrenia and in reducing the rate of relapse for up to 52 weeks.

Although results of a limited comparative study suggest that oral ziprasidone hydrochloride dosages of 160 mg daily may be as effective as oral haloperidol 15 mg daily in reducing positive symptoms of schizophrenia, a reliable and valid comparison of ziprasidone and oral haloperidol cannot be made at this time based solely on this study due to its relatively small sample size (90 Patients), high dropout rate (51.1%), and brief duration (4 weeks). Data from one unpublished comparative study also suggest that ziprasidone hydrochloride (mean dosage of 130 mg daily) may be as effective as olanzapine (mean dosage of 11 mg daily) in the treatment of schizophrenia.

Ziprasidone is used IM for the management of acute agitation in patients with schizophrenia for whom treatment with ziprasidone is appropriate and who require an IM antipsychotic agent for rapid control of behaviors that interfere with diagnosis and care (e.g., threatening behaviors, escalating or ur-Bently distressing behavior, self-exhausting behavior). The efficacy of IM ziprasidone for the management of acute agitation in schizophrenia was established in single-day controlled trials in hospital settings. Because there is no experience regarding the safety of administering ziprasidone IM to schiz-

ophrenic patients already receiving oral and IM formulations of ziprasidone is no




EXHIBIT Case 2:11-cv 00236-JPC Filed 11/26/13 Page 1 of 3 Document 171-4

ATYPICAL ANTIPSYCHOTICS phrenia, see Uses: Psychoneurologic Disorders, in the Phenothiazines General Statement 28:16.08.24.

### **Dosage and Administration**

Administration Ziprasidone hydrochloride is administered orally twice daily with food. Ziprasidone mesylate is administered only by IM injection.

The commercially available lyophilized powder of ziprasidone mesylate for injection must be reconstituted prior to administration by adding 1.2 mL of sterile water for injection to single-dose vials of ziprasidone to provide a solution containing 20 mg/mL. Other solutions should not be used to reconstitute ziprasidone mesylate injection, and the drug should not be admixed with other drugs. The vials should then be shaken vigorously to ensure complete dissolution. Strict aseptic technique must be observed since the drug contains no preservative. Following reconstitution, ziprasidone mesylate for injection is stable for 24 hours when protected from light and stored at 15-30°C or for up to 7 days when refrigerated at 2-8°C. Ziprasidone mesylate injection should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

■ Dosage : Dosage of ziprasidone hydrochloride is expressed in terms of the hydrochloride monohydrate. Dosage of ziprasidone mesylate is expressed in terms of ziprasidone.

Oral Dosage For the symptomatic management of schizophrenia, the recommended initial adult dosage of ziprasidone hydrochloride is 20 mg twice daily. Dosage may be increased after a minimum of 2 days at each dosage up to a maximum recommended dosage of 80 mg twice daily. To ensure use of the lowest effective dosage, however, it is recommended that patients be observed for several weeks prior to upward titrations of ziprasidone dosages. While a relationship between dosage and antipsychotic effect has not been established, the effective dosage of ziprasidone hydrochloride in clinical studies generally ranged from 20-100 mg twice daily. The manufacturer states that dosages exceeding 80 mg twice daily generally are not recommended, and safety of ziprasidone hydrochloride in dosages exceeding 100 mg twice daily has not been established.

The optimum duration of ziprasidone therapy currently is not known, but maintenance therapy with ziprasidone hydrochloride 20-80 mg twice daily has been shown to be effective for up to 52 weeks. However, the manufacturer states that no additional benefit has been demonstrated for ziprasidone hydrochloride dosages beyond 20 mg twice daily. Patients responding to ziprasidone therapy should continue to receive the drug as long as clinically necessary and tolerated, but at the lowest possible effective dosage, and the need for continued therapy with the drug should be reassessed periodically.

IM Dosage For the prompt control of acute agitation in patients with schizophrenia, the recommended initial adult IM dose of ziprasidone is 10-20 ing given as a single dose. Depending on patient response, doses of 10 or 20 mg may be repeated every 2 or 4 hours, respectively, up to a maximum cumulative dose of 40 mg daily.

Oral therapy should replace IM therapy as soon as possible. Safety and efficacy of administering ziprasidone mesylate IM injection for longer than 3 consecutive days have not been evaluated. Because there is no experience regarding the safety of administering ziprasidone mesylate IM injection to patients with schizophrenia who already are receiving oral ziprasidone hydrochloride, the concomitant use of oral and IM formulations of ziprasidone is not recommended by the manufacturer.

 Special Populations No special population dosage recommendations at this time. Note that the second of the

#### Cautions

Contraindications Known history of QT prolongation (including congenital long QT syndrome), recent acute myocardial infarction, or uncompensated heart failure. (See Prolongation of QT Interval under Warnings/Precautions: Warnings, in Cautions.) Concomitant therapy with other drugs that prolong the QT interval. (See Drug Interactions: Drugs that Prolong QT Interval.) Known hypersensitivity to ziprasidone.

■ Warnings/Precautions Warnings Prolongation of QT Interval. Prolongation of the QT interval can result in an occurrence of ventricular arrhythmias (e.g., torsades de pointes) and/or sudden death. In one study, oral ziprasidone prolonged the QT interval on ECG by a mean of 9-14 msec more than that observed in patients receiving risperidone, olanzapine, quetiapine, or haloperidol, but approximately 14 msec less than that observed in patients receiving thioridazine. In a study evaluating the QT/QT, prolongation effect of IM ziprasidone, the mean increase in QTc from baseline following 2 IM injections of ziprasidone (20 mg, then 30 mg, which is 50% higher than the recommended therapeutic dose) or haloperidol (7.5 mg, then 10 mg), given 4 hours apart, was 12.8 or 14.7 msec, respectively. Therefore, although torsades de pointes was not associated with ziprasidone therapy when the drug was administered at recommended dosages in premarketing clinical studies, experience with the drug is too limited to rule out the possibility that ziprasidone may

**AHFS DRUG INFORMATION® 2005** 

2319

be associated with a greater risk of sudden death than other antipsychotic agents. Patients at particular risk of torsades de pointes and/or sudden death include those with bradycardia, hypokalemia, or hypomagnesemia, those receiving concomitant therapy with other drugs that prolong the QT<sub>e</sub> interval, and those with congenital prolongation of QTe interval. The manufacturer states that ziprasidone should be avoided in patients with congenital prolongation of the QT interval or a history of cardiac arrhythmias and in those receiving concomitant therapy with other drugs that prolong the QTc interval. (See Cautions: Contraindications and Drug Interactions: Drugs that Prolong QT Interval.)

Baseline serum potassium and magnesium concentrations should be determined in patients at risk for substantial electrolyte (i.e., potassium, magnesium) disturbances, particularly those receiving concomitant diuretic therapy, and hypokalemia or hypomagnesemia should be corrected prior to initiating ziprasidone. Clinical and ECG monitoring of cardiac function, including appropriate ambulatory ECG monitoring (e.g., Holter monitoring), is recommended during ziprasidone therapy in patients with symptoms that could indicate torsades de pointes (e.g., dizziness, palpitations, syncope). Ziprasidone therapy should be discontinued if the QT<sub>e</sub> interval exceeds 500 msec.

Neuroleptic Malignant Syndrome. Although no cases have been confirmed to date in patients receiving ziprasidone, neuroleptic malignant syndrome (NMS), a potentially fatal syndrome requiring immediate discontinuance of the drug and intensive symptomatic treatment, may occur in patients receiving antipsychotic agents. For additional information on NMS, see Extrapyramidal Reactions under Cautions: Nervous System Effects, in the Phenothiazines General Statement 28:16.08.24.

Tardive Dyskinesia. Like other antipsychotic agents, use of ziprasidone may be associated with tardive dyskinesias, a syndrome of potentially irreversible, involuntary, dyskinetic movements. Although emergence of tardive dyskinesia was not specifically evaluated in clinical studies of ziprasidone, use of the drug was associated with either no change or small reductions in the Abnormal Involuntary Movement Scale (AIMS) scores from baseline in one year-long study of the drug. However, differences among antipsychotic agents in their potential to cause tardive dyskinesia have not been established definitively. For additional information on tardive dyskinesia, see Cautions: Nervous System Effects, in the Phenothiazines General Statement 28:16.08.24.

Hyperglycemia and Diabetes Mellitus. Severe hyperglycemia, sometimes associated with ketoacidosis, hyperosmolar coma, or death, has been reported in patients receiving certain atypical antipsychotic agents (e.g., clozapine, olanzapine, quetiapine, risperidone). While confounding factors such as an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population make it difficult to establish with certainty the relationship between use of agents in this drug class and glucose abnormalities, epidemiologic studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotic agents included in the studies (e.g., clozapine, olanzapine, quetiapine, risperidone); it remains to be determined whether ziprasidone also is associated with this increased risk. Although there have been few reports of hyperglycemia or diabetes in patients receiving ziprasidone, it is not known whether the paucity of such reports is due to relatively limited experience with the drug.

Precise risk estimates for hyperglycemia-related adverse events in patients treated with atypical antipsychotics currently are not available. While some evidence suggests that the risk for diabetes may be greater with some atypical antipsychotics (e.g., clozapine, olanzapine) than with others (e.g., quetiapine, risperidone) in the class, available data are conflicting and insufficient to provide reliable estimates of relative risk associated with use of the various atypical antipsychotics.

The manufacturers of atypical antipsychotic agents state that patients with preexisting diabetes mellitus in whom therapy with an atypical antipsychotic is initiated should be closely monitored for worsening of glucose control; those with risk factors for diabetes (e.g., obesity, family history of diabetes) should undergo fasting blood glucose testing upon therapy initiation and periodically throughout treatment. Any patient who develops manifestations of hyperglycemia during treatment with an atypical antipsychotic should undergo fasting blood glucose testing. In some cases, patients who developed hyperglycemia while receiving an atypical antipsychotic have required continuance of antidiabetic treatment despite discontinuance of the suspect drug; in other cases, hyperglycemia resolved with discontinuance of the antipsychotic.

For further information on managing the risk of hyperglycemia and diabetes mellitus associated with atypical antipsychotic agents, see Hyperglycemia and Diabetes Mellitus under Cautions: Precautions and Contraindications, in Clozapine 28:16.04.

Sensitivity Reactions Rash. Rash and/or urticaria, possibly related to dose and/or duration of therapy, occurred in about 5% of patients in clinical studies and have necessitated discontinuance of the drug in about 17% of these patients. Adjunctive treatment with antihistamines or steroids and/or drug discontinuance may be required. Discontinue ziprasidone if alternative etiology of rash cannot be identified.

General Precautions Cardiovascular Effects. Orthostatic hypotension, particularly during initial dosage titration period, has been reported. Use with caution in patients with known cardiovascular or cerebrovascular disease 2320

**AHFS DRUG INFORMATION® 2005** 

and/or conditions that would predispose patients to hypotension (e.g., dehy, dration, hypovolemia, concomitant antihypertensive therapy).

Seizures occurred in about 0.4% of patients Nervous System Effects. Nervous System Enects. Betrates beaution to be with caution in patients receiving ziprasidone in controlled clinical trials. Use with caution in patients with a history of seizures or with conditions known to lower the seizure thresh old (e.g., Alzheimer's disease, geriatric patients).

(e.g., Alzneinier's disease, germine parents, a particular and a parents of the second and the s Although not reported in chine at stores when associated with the body's ability to reduce core body temperature has been associated with use body's ability to reduce core body temperature to an elevation in core to the second s patients exposed to conditions that may contribute to an elevation in core body temperature (e.g., dehydration, extreme heat, strenuous exercise, concomitant use of anticholinergic agents).

GI Effects. Esophageal dysmotility and aspiration have been associ-Gt Effects. Esophagean dystreamly line with caution in patients at risk with the use of antipsychotic agents. Use with educated at risk for aspiration pneumonia (e.g., geriatric patients, those with advanced Al<sub>zhei</sub>. mer's dementia).

Suicide. Attendant risk with psychotic illnesses; closely supervise high-risk patients. Prescribe in the smallest quantity consistent with  $good p_{a}$ . tient management to reduce the risk of overdosage.

Sexual Dysfunction. One case of drug-induced priapism reported in clinical studies of ziprasidone.

Other Metabolic and Endocrine Effects. Prolactin concentrations ex. ceeding 22 ng/mL were reported in about 20% of patients receiving ziprasidone in phase II or III clinical studies compared with about 4, 46, or 89% of those receiving placebo, haloperidol, or risperidone, respectively.

Median weight gain of 0.5 kg occurred in patients receiving ziprasidone compared with no median weight change in those receiving placebo. In clinical studies, ziprasidone reportedly caused less weight gain than clozapine, olanzapine, quetiapine, or risperidone.

For additional information on metabolic effects, see Hyperglycemia and Diabetes Mellitus under Warnings/Precautions: Warnings, in Cautions.

Specific Populations Pregnancy. Category C. (See Users Guide.) Not known whether ziprasidone is distributed in milk; use Lactation.

in nursing women is not recommended.

Pediatric Use. Safety and efficacy not established in children younger than 18 years of age.

Geriatric Use. No substantial differences in safety of oral ziprasidone relative to younger adults. Ziprasidone mesylate IM injections have not been systematically evaluated in geriatric patients. Lower initial dosages, slower titration, and more careful monitoring during the initial dosing period may be advisable in some geriatric patients.

Renal Impairment. Commercially available ziprasidone mesylate injections contain sulfobutylether  $\beta$ -cyclodextrin sodium, an excipient that is cleared by renal filtration. Therefore, ziprasidone injection should be used with caution in patients with renal impairment.

Common Adverse Effects Adverse effects occurring in more than 5% of patients receiving oral ziprasidone and at least twice the frequency of placebo include somnolence (14%), extrapyramidal syndrome (5%), and respiratory disorder (8%).

Adverse effects occurring in more than 5% of patients receiving IM ziprasidone 10 or 20 mg and at a frequency twice that reported among those receiving IM ziprasidone 2 mg include somnolence (20%), headache (13%), and nausea (12%).

### **Drug Interactions**

Drugs that Prolong QT Interval Potential pharmacologic interaction (additive effect on QT interval prolongation; concomitant use contraindicated) when ziprasidone is used with drugs that are known or consistently observed to prolong the  $QT_e$  interval (e.g., dofetilide, sotalol, quinidine, other Class Ia and III antiarrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate [no longer commercially available in the US], dolasetron mesylate, probucol, tacrolimus). Ziprasidone also is contraindicated in patients receiving drugs shown to cause QT prolongation as an effect and for which this effect is described in the full prescribing information as a contraindication or a boxed or bolded warning. (See Cautions: Contraindications and Prolongation of QT interval under Warnings/Precautions: Warnings in Cautions.)

Hypotensive Agents Potential pharmacologic interaction (additive hypotensive effects).

■ Other CNS Agents Potential pharmacologic interaction (additive sedative effects).

Levodopa and Dopamine Agonists Potential pharmacologic interaction (antagonistic effects).

Drugs Affecting Hepatic Microsomal Enzymes Inhibitors or int ducers of cytochrome P-450 (CYP) 3A4 isoenzyme; potential pharmacokinetic interaction (altered metabolism). Inhibitors or inducers of CYP1A2, CYP2C9, CYP2C19, or CYP2D6 isoenzymes: pharmacokinetic interaction unlikely.

Protein-bound Drugs Pharmacokinetic interaction unlikely.

## pescription

Ziprasidone is a benzisothiazolyl piperazine-derivative antipsychotic agent that is chemically unrelated to other currently available antipsychotic agents (e.g., butyrophenones, phenothiazines) and has been referred to as an atypical antipsychotic agent. The exact mechanism of antipsychotic action of ziprasidone has not been fully elucidated but, like that of other atypical antipsychotic agents (e.g., olanzapine, risperidone), may involve antagonism of central type 2 serotonergic (5-HT<sub>2</sub>) receptors and central dopamine D<sub>2</sub> receptors. Antagonism of various other receptors (e.g., histamine H<sub>1</sub> receptors,  $\alpha_1$ -adrenergic receptors) may contribute to other therapeutic and adverse effects (e.g., orthostatic hypotension, somnolence) observed with ziprasidone.

Ziprasidone is extensively metabolized in the liver principally via reduction by aldehyde oxidase with minimal excretion of unchanged drug in urine (<1%) or feces (<4%). About one-third of ziprasidone's metabolic clearance is mediated by the cytochrome P-450 (CYP) 3A4 isoenzyme. Ziprasidone did not inhibit CYP1A2, 2C9, 2C19, 2D6, or 3A4 isoenzymes in vitro.

### Advice to Patients

Importance of reading manufacturer's patient information.

Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription (see Drug Interactions: Drugs That Prolong QT Interval) or OTC drugs, dietary supplements, and/or herbal products, as well as any concomitant illnesses (e.g., cardiovascular disease, diabetes mellitus).

Because somnolence and impairment of judgment, thinking, or motor skills may be associated with ziprasidone, avoid driving, operating machinery, or performing hazardous tasks while taking ziprasidone until gain experience with the drug's effects.

Importance of taking medication exactly as prescribed by the clinician.

Importance of women informing clinicians immediately if they are or plan to become pregnant or plan to breast-feed.

Overview (see Users Guide). For additional information until a more detailed monograph is developed and published, the manufacturer's labeling should be consulted. It is *essential* that the manufacturer's labeling be consulted for more detailed information on usual cautions, precautions, contraindications, potential drug interactions, laboratory test interferences, and acute toxicity.

control in accurating an explanation in solid on all extent of the second second second second second second se

Preparations

Oral	a-9172 9749870 577 - 91798 1	And the second	
Capsules	20 mg	Geodon", Pfizer	413 H
of the second of the	40 mg	Geodon*, Pfizer	- W. L. K
HILLONG TO -P	60 mg	Geodon*, Pfizer	÷
SCOLOTE TO LAR	80 mg	Geodon*, Pfizer	-3
Ziprasidone	Mesylate	s sa fi skan i s	an Tène
Parenteral	the second second second	Second Second	1.10
For Injection, for IM use only	20 mg (of ziprasidone) per mL	Geodon <sup>®</sup> (with sulfol cyclodextrin sodium 2 Pfizer	
Selected Revisions Pharmacists, Inc.	Ianuary 2005, © Copyright, September		Health-System

Haloperidol
Haloperidol is a butyrophenone-derivative antipsychotic agent.
Uses

■ Psychotic Disorders Haloperidol is used for the symptomatic management of psychotic disorders. Drug therapy is integral to the management of acute psychotic episodes and accompanying violent behavior in patients with schizophrenia and generally is required for long-term stabilization to improve symptoms between episodes and to minimize the risk of recurrent acute episodes. Antipsychotic agents are the principal class of drugs used for the management of all phases of schizophrenia and generally are effective in all subtypes of the disorder and subgroups of patients. Conventional antipsychotic agents, such as haloperidol, generally are considered to exhibit similar efficacy in treating acute psychotic symptoms, although they vary in their potency and

Haloperidol

BUTYROPHENONES

28:16.08.08

adverse effect profile. Haloperidol is a high-potency antipsychotic that has been shown to be effective in the management of acute and stable phases of schizophrenia, but is frequently associated with extrapyramidal reactions such as akathisia, dystonia, or parkinsonian symptoms, even at low dosages.

Results of short-term studies indicate that haloperidol is more effective than placebo and equally or less effective than atypical antipsychotics in the treatment of positive (e.g., delusions, hallucinations) and negative symptoms (e.g., withdrawal from social interaction, blunted emotional expression) of schizophrenia. However, in one clinical study, haloperidol was less effective than the atypical antipsychotic agent risperidone in preventing relapse in adult outpatients with clinically active schizophrenia or schizoaffective disorders who were assigned to receive either drug for a minimum of 1 year. In this study, approximately 40% of patients in the study who received usual dosages of haloperidol had relapsed by the end of the study compared with approximately 25% of those receiving usual dosages of risperidone. Because atypical antipsychotics appear to be at least as effective in the treatment of positive symptoms and possibly more effective in the treatment of negative symptoms of schizophrenia and have fewer extrapyramidal reactions, some clinicians prefer use of atypical antipsychotics rather than conventional antipsychotics, such as haloperidol, for the management of schizophrenia, except in stable patients who have had good response to conventional antipsychotics without major adverse effects, in patients who require IM therapy, which is not yet available for atypical antipsychotics, and for the acute management of aggression/violence in some patients, particularly those requiring long-acting (depot) parenteral preparations. However, patient response and tolerance to antipsychotic agents are variable, and patients who do not respond to or tolerate one drug may be successfully treated with an agent from a different class or with a different adverse effect profile.

The long-acting decanoate ester of haloperidol is used parenterally principally in patients requiring prolonged antipsychotic therapy (e.g., patients with chronic schizophrenic disorder). Parenteral antipsychotic therapy with a longacting preparation may be particularly useful in patients with a history of poor compliance. In addition, long-acting antipsychotic preparations may be useful in patients with suspected GI malabsorption or variable GI absorption of the drug. The principal disadvantage of long-acting parenteral antipsychotics is the inability to terminate the drug's action when severe adverse reactions occur. Long-acting antipsychotic preparations should not be used in the acute management of severely agitated patients. Generally, patients should be stabilized on antipsychotic medication prior to conversion to haloperidol decanoate therapy and should have previously received and tolerated a shorter-acting haloperidol preparation so that the possibility of an unexpected adverse reaction that potentially could not be readily reversed following the decanoate can be minimized. For further information on the use of antipsychotic agents in the symptomatic treatment of schizophrenia, see Uses: Psychoneurologic Disorders in the Phenothiazines General Statement 28:16.08.24:

■ Tourette's Syndrome Haloperidol is used for the control of tics and vocal utterances of Tourette's syndrome (Gilles de la Tourette's syndrome) in children and adults. Haloperidol generally has been considered the drug of choice for the management of Tourette's syndrome and pimozide has been be an effective alternative in some patients who have an inadequate response to or do not tolerate haloperidol. Because limited data suggest that pimozide may be more effective than haloperidol in reducing tics and pimozide appears to be better tolerated than haloperidol, some clinicians and experts prefer the use of pimozide in patients with Tourette's syndrome.

In children with tic disorders (e.g., Tourette's syndrome) and comorbid attention deficit hyperactivity disorder† (ADHD) in whom stimulants alone cannot control tics, haloperidol may be used concomitantly with a stimulant.

**Delirium** Antipsychotic agents, mainly haloperidol, have been used in the management of delirium<sup>†</sup>.

**General Considerations** Delirium is principally a disturbance of consciousness, attention, cognition, and perception but also may affect sleep, psychomotor activity, and emotions. It is a common psychiatric illness among medically compromised patients, particularly hospitalized patients, and may be a harbinger of substantial morbidity and mortality.

Prevalence and Course The prevalence of delirium in hospitalized medically ill patients ranges from 10-30%; in those who are elderly, delirium ranges up to 40%. Up to 25% of hospitalized cancer patients and 30-40% of hospitalized patients with acquired immunodeficiency syndrome ( AIDS) develop delirium. Up to about 50% of postoperative patients develop delirium, and up to 80% of terminally ill patients develop it near death. EEG abnormalities, mainly generalized slowing, have fairly good sensitivity for aiding in the diagnosis of delirium, but the absence of such changes does not rule out the diagnosis. Prodromal manifestations may progress to full-blown delirium over 1-3 days; the duration of delirium generally ranges from less than a week to more than 2 months, but typically does not exceed 10-12 days. Symptoms persist for up to 30 days or longer in up to 15% of patients, and frequently persist for longer than 1 month in geriatric patients. Although most patients recover fully, delirium may progress to stupor, coma, seizures, and death, particularly if untreated. Full recovery is less likely in geriatric patients and patients with AIDS, possibly because of underlying dementia in both populations.

Underlying general medical conditions associated with delirium include CNS disorders (e.g., head trauma, seizures, postictal state, vascular or degen-AHES DRUG INFORMATION® 2005 2321

Case 2:11-cv-00236-JPS Filed 11/26/13 Page 3 of 3 Document 171-4

Persons	U.S. (mg)	Canada (mg)
Infants and children Birth to 3 years of age 4 to 6 years of age 7 to 10 years of age	5-10 10 10	2-4 5 7-9

Deficiency (treatment)-

Treatment dose is individualized by prescriber based on severity of deficiency.

[Copper absorption inhibitor]1-

Oral, 22.5 to 34 mg elemental zinc three times a day.

### Strength(s) usually available

U.S.

25 mg elemental zinc (110 mg zinc sulfate) (OTC) [Orazinc].

- 50 mg elemental zinc (220 mg zinc sulfate) [Orazinc (OTC); Verazinc (OTC); Zinc-220 (OTC); Zincate (Rx); GENERIC (Rx/OTC)].
- Canada-

Not commercially available.

Note: The strength of these zinc preparations may exceed the dosage range recommended by USP DI Advisory Panels based on the amount necessary to meet normal nutritional needs.

#### Packaging and storage

Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight container.

### ZINC SULFATE TABLETS

Usual adult and adolescent dose

### See Zinc Sulfate Capsules.

#### Usual pediatric dose

See Zinc Sulfate Capsules.

### Strength(s) usually available

U.S.-

- 15 mg elemental zinc (66 mg zinc sulfate) (OTC) [Zinc 15].
- 25 mg elemental zinc (110 mg zinc sulfate) (OTC) [Orazinc].
- 45 mg elemental zinc (200 mg zinc sulfate) (Rx/OTC).
- 50 mg elemental zinc (220 mg zinc sulfate) (Rx).

#### Canada-

50 mg elemental zinc (220 mg zinc sulfate) (OTC) [PMS Egozinc].

Note: The strength of these zinc preparations may exceed the dosage range recommended by USP DI Advisory Panels based on the amount necessary to meet normal nutritional needs.

#### Packaging and storage

Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight container

### ZINC SULFATE EXTENDED-RELEASE TABLETS

Usual adult and adolescent dose

### See Zinc Sulfate Capsules.

Usual pediatric dose

### See Zinc Sulfate Capsules.

### Strength(s) usually available

U.S.

50 mg elemental zinc (220 mg zinc sulfate) (OTC). Canada-

Not commercially available.

Note: The strength of this zinc preparation may exceed the dosage range recommended by USP DI Advisory Panels based on the amount necessary to meet normal nutritional needs.

### Packaging and storage

Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Store in a tight container.

### Parenteral Dosage Forms

#### ZINC SULFATE INJECTION USP

Note: Injectable zinc products must be diluted prior to intravenous administration.

#### Usual adult and adolescent d

- Deficiency (prophylaxis or treatment Intravenous infusion, 2.5 to 4 m total parenteral nutrition (TPI
- Note: Some clinicians recommend allow for excessive zinc losse as diarrhea.



### Usual pediatric dose

Deficiency (prophylaxis or treatment)-

- Intravenous infusion: For full term infants and children up to 5 years of age: 100 mcg of elemental zinc per kg of body weight a day, For premature infants (up to 3 kg of body weight): 300 mcg of ele-
- mental zinc per kg of body weight a day added to TPN.
- Note: Zinc injection that contains benzyl alcohol as a preservative should Zinc injection that contains being a second should not be used in newborn and immature infants. The use of benzyl alcohol in neonates has been associated with a fatal toxic syndrome consisting of metabolic acidosis and CNS, respiratory, circulatory, and renal function impairment.

#### Strength(s) usually available

#### U.S.

- 1 mg of elemental zinc (4.39 mg zinc sulfate) per mL (Rx) [*Zinca-Pak* (0.9% benzyl alcohol)].
- 5 mg of elemental zinc (21,95 mg zinc sulfate) per mL (Rx) [Zinca-Pak].

### Canada-

Not commercially available.

### Packaging and storage

Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F), unless otherwise specified by manufacturer. Protect from freezing.

### Preparation of dosage form

Zinc sulfate is physically compatible with amino acid solutions, dextrose solutions, and injectable vitamin preparations.

1Not included in Canadian product labeling.

Revised: 09/08/2000

#### ZIPRASIDONE Systemic<sup>†</sup>

### VA CLASSIFICATION (Primary): CN709

Commonly used brand name(s): Geodon.

Note: For a listing of dosage forms and brand names by country availability, see Dosage Forms section(s).

†Not commercially available in Canada.

#### Category

Antipsychotic,

### Indications

#### Accepted

Schizophrenia (treatment)-Ziprasidone is indicated for the treatment of schizophrenia.

### Pharmacology/Pharmacokinetics

#### Physicochemical characteristics Molecular weight-467.42

### Mechanism of action/Effect

The exact mechanism of action of ziprasidone is unknown. It is thought that the drug's efficacy in the treatment of schizophrenia is mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5-HT<sub>2</sub>) antagonism. Antagonism at receptors other than those listed that have similar receptor affinities may explain some of the other therapeutic and side effects of ziprasidone.

#### Absorption

Ziprasidone is well absorbed after oral administration. Absolute bioavailability of a 20-mg dose under fed conditions is approximately 60%. Absorption is increased up to two-fold in the presence of food.

#### Distribution

Mean apparent Volume of Distribution (Vol<sub>p</sub>)-1.5 L per kilogram of body weight (L/kg).

### Protein binding

- Very high (> 99%) to plasma proteins. It is primarily bound to albumin and  $\alpha_1$ -acid glycoprotein.
- The in vitro plasma protein binding of ziprasidone was not altered by warfarin or propranolol, nor did ziprasidone alter the binding of these two drugs in human plasma. The potential for drug interactions due to displacement is minimal.

© 2005 Thomson MICBOMEDEX Altrights represed. Filed 11/26/1988 Patronantol upda Bootime htp://spetmicromedex.com

#### 3009 Ziprasidone (Systemic)

#### USP DI

#### Biotransformation

Ziprasidone is primarily cleared via hepatic metabolism, by three metabolic routes, to yield benzisothiazole (BITP) sulphoxide, BITP-sulphone, ziprasidone sulphoxide and S-methyl-dihydroziprasidone.

#### Half-life

Elimination-Mean terminal half-life is about 7 hours.

#### Time to peak concentration

6 to 8 hours

#### Flimination

Renal-20 %, < 1% as unchanged drug. Fecal-66 %, < 4% as unchanged drug.

### **Precautions to Consider**

#### Carcinogenicity

- Lifetime carcinogenicity studies were done in Long Evans rats and CD-1 mice. Ziprasidone was administered for 24 months at doses of 2, 6, or 12 mg/kg/day in rats and 50, 100, or 200 mg/kg/day in mice (0.1 to 0.6 times the maximum recommended human dose [MRHD] of 200 mg/day on a mg/m<sup>2</sup> basis, respectively).
- In the rat study there was no evidence of an increased incidence of tumors. In the mice, male mice there was no evidence of an increased incidence of tumors. In female mice there were dose related increases in the incidences of pituitary gland adenoma and carcinomas, and mammary gland adenocarcinoma at all doses tested (50 to 200 mg/ kg/day or 1 to 5 times the MRHD on a mg/m<sup>2</sup> basis). Proliferative changes in the pituitary gland and mammary glands of rodents have been observed following chronic administration of other antipsychotic agents and are considered to be prolactin mediated.
- Increases in serum prolactin were observed in a 1-month dietary study in female mice at doses of 100 and 200 mg/kg/day (or 2.5 and 5 times the MRHD on a mg/mg<sup>2</sup> basis). Ziprasidone had no effect on serum prolactin in rats in a 5 week dietary study at the doses used in the carcinogenicity study. The relevance for human risk of the findings of the prolactin-mediated endocrine tumors in rodents is unknown.

#### Mutagenicity

Ziprasidone was tested in the Ames bacterial mutation assay, the in vitro mammalian cell gene mutation mouse lymphoma assay, the in vitro chromosomal aberration assay in human lymphocytes, and the in vivo chromosomal aberration in mouse bone marrow. There was a reproducible mutagenic response in the Ames assay in one strain of S. typhimurium in the absence of metabolic activation. Positive results were obtained in both the in vitro mammalian cell gene mutation assay and the in vitro chromosomal aberration assay in human lymphocytes.

#### Pregnancy/Reproduction

Fertility---Ziprasidone was shown to increase copulation time in Sprague-Dawley rats in two fertility and early embryonic development studies at doses of 10 to 160 mg/kg/day (0.5 to 8 times the MRHD of 200 mg/ day on a mg/m<sup>2</sup> basis). Fertility rate was reduced at doses of 160 mg/ kg/day (8 times the MRHD of 200 mg/day on a mg/m<sup>2</sup> basis). The effect on fertility appeared to be in the female since fertility was not impaired when males given 160 mg/kg/day (8 times the MRHD of 200 mg/day on a mg/m<sup>2</sup> basis) were mated with untreated females. In a 6 month study in male rats given 200 mg/kg/day (10 times the MRHD on a mg/m<sup>2</sup> basis) there were no treatment related findings observed in the testes

Pregnancy-There are no adequate and well controlled studies in humans.

- Developmental toxicity was demonstrated in animal studies, including possible teratogenic effects at doses similar to human therapeutic doses. When ziprasidone was administered to pregnant rabbits during organogenesis, an increased incidence of fetal structural abnormalities (ventricular septal defects and other cardiovascular malformations and kidney alterations) were observed at doses of 30 mg/kg/day (3 times the MRHD of 200 mg/ day on a mg/m2 basis). There was no evidence to suggest that these developmental effects were secondary to maternal toxicity.
- The developmental no effect dose was 10 mg/kg/day (equivalent to the MRHD on a mg/m<sup>2</sup> basis). In rats, embryofetal toxicity (decreased fetal weights, delayed skeletal ossification) was observed following administration of 10 to 160 mg/kg/day (0.5 to 8 times the MRHD of 200 mg/ day on a mg/m<sup>2</sup> basis) during organogenesis or throughout gestation, but there was no evidence of teratogenicity. Doses of 40 and 60 mg/ kg/day (2 and 8 times the MRHD on a mg/m<sup>2</sup> basis) were associated with maternal toxicity. The developmental no-effect dose was 5 mg/ kg/day (0.2 times the MRHD of 200 mg/day on a mg/m<sup>2</sup> basis).
- There was an increase in the number of pups born dead and a decrease in postnatal survival throughout the first 4 days of lactation among the offspring of female rats treated during gestation and lactation with doses of 10 mg/kg/day (0.5 times the MRHD of 200 mg/day on a mg/ Case 2:11-CV-00236-JPS File0 11/26/13 © 2005 Thomson MICROMEDEX All rights reserved.

m<sup>2</sup> basis) or greater. Offspring developmental delays and neurobehavioral functional impairment were observed at doses of 5 mg/kg/day (0.2 times the MRHD of 200 mg/day on a mg/m<sup>2</sup> basis) or greater. A no-effect level was not established for these effects.

Effect on labor and delivery is unknown.

FDA Pregnancy Category C

#### Breast-feeding

Is is not known whether ziprasidone is distributed into human breast milk. Breast-feeding is not recommended in women receiving ziprasidone.

#### Pediatrics

No information is available on the relationship of age to the effects of ziprasidone in the pediatric population. Safety and efficacy have not been established.

#### Geriatrics

Although appropriate studies on the relationship of age to the effects of ziprasidone have not been performed, geriatrics-specific problems are not expected to limit the usefulness of ziprasidone in the elderly. However, elderly patients are more likely to age-related medical problems which may require a lower starting dose, slower titration, and careful monitoring during the initial dosing period.

#### Drug interactions and/or related problems

- The following drug interactions and/or related problems have been selected on the basis of their potential clinical significance (possible mechanism in parentheses where appropriate)-not necessarily inclusive (>> = major clinical significance):
- Note: Combinations containing any of the following medications, depending on the amount present, may also interact with this medication.

#### Antihypertensive agents

(ziprasidone has the potential for inducing hypotension, and it may enhance the effects of certain antihypertensive agents; risk of priapism increases with concomitant use of ziprasidone and alphaadrenergic blocking agents)

#### Carbamazepine

(may decrease the AUC of ziprasidone, this effect may be greater as doses increase)

- CNS stimulation-producing medications (see Appendix II) and
- CNS depression-producing medications (see Appendix II) (given the primary CNS effects of ziprasidone caution should be used when using other centrally acting drugs)

#### Ketoconazole and

CYP3A4 hepatic enzyme inhibitors, other (may increase the AUC and the  $C_{max}$  of ziprasidone)

Levodopa and

#### Dopamine agonists

(ziprasidone may antagonize the effects of these drugs)

QT Interval prolongation drugs, including:

Arsenic trioxide

- Chlorpromazine
- Class Ia and III anti-arrhythmics
  - Dofetilide
  - Dolasetron mesylate
- Droperidol Gatifloxacin
- Halofantrine
- Levomethadyl acetate
- Mefloquine
- Mesoridazine
- Moxifloxacin
- Pentamidine
- Pimozide
- Probucol
- Quinidine
- Sotalol Sparfloxacin
- Tacrolimus
  - Thioridazine

(concurrent use of these medications with ziprasidone is contraindicated; dose related prolongation of the QT interval with ziprasidone and the known associated fatal arrhythmias with QT prolongation by some other drugs; associated with torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death.)

#### Laboratory value alterations

The following have been selected on the basis of their potential clinical significance (possible effect in parentheses where appropriate)-not necessarily inclusive (» = major clinical significance). Page 2 of 4 Document 171-5 Access FREE monthly updates online at <u>http://uspdi.micromedex.com</u>

ars lay, эleuld IZy| yncir-

° DI

nd )m se

°ak

ca-

#### 3010 Ziprasidone (Systemic)

With physiology/laboratory test values

Prolactin

(ziprasidone elevates prolactin levels, clinical significance is unknown; hyperprolactinemia linked to one-third of human breast cancers, in vitro, but no studies to date associate ziprasidone and tumorigenesis in humans)

### Medical considerations/Contraindications

The medical considerations/contraindications included have been selected on the basis of their potential clinical significance (reasons given in parentheses where appropriate)-not necessarily inclusive (>> = major clinical significance).

#### Except under special circumstances, this medication should not be used when the following medical problem exists: >>

Acute myocardial infarction, recent, or

Bradycardia

Cardiac arrhythmias, history of, or

QT prolongation, history of or congenital, or

Heart failure, uncompensated

(certain cardiovascular circumstances may increase the risk of QT prolongation, arrhythmia, torsade de pointes, and risk of sudden death)

#### » Hypersensitivity to ziprasidone

Uncorrected electrolyte disorders, including: >>

Hypokalemia

Hypomagnesemia

(may increase the risk of QT prolongation, arrhythmia, torsade de pointes, and risk of sudden death)

#### Risk-benefit should be considered when the following medical problems exist:

Neuroleptic Malignant Syndrome (NMS)

- (potentially fatal symptom complex [e.g., hyperpyrexia, muscle rigidity, altered mental status, evidence of autonomic instability, elevated creatinine phosphokinase, myoglobinuria, acute renal failure] has been reported in association with administration of antipsychotic drugs; management includes immediate discontinuation of the antipsychotic drugs and other non-necessary drugs, intensive symptomatic treatment and medical monitoring and treatment of any comitant serious medical problems for which there is a treatment; after recovery from NMS, if antipsychotic therapy is required, careful monitoring is warranted as antipsychotic therapy is reintroduced)
- Tardive Dyskinesia

(potentially irreversible, involuntary, dyskinetic movements may develop in patients undergoing treatment with antipsychotic drugs; more likely to occur in the elderly, especially elderly women; risk of irreversible tardive dyskinesia increases with duration of treatment and total cumulative dose; therapy should be given at the smallest dose and for the shortest duration; if signs and symptoms of tardive dyskinesia appear, consider drug discontinuation; some patients may require treatment with ziprasidone despite the presence of the syndrome)

Seizures, history of, or

Alzheimer's dementia

(use with caution in patients with a history of seizures or with conditions that potentially lower the seizure threshold; use with caution due to increased risk of aspiration pneumonia)

#### Patient monitoring

- The following may be especially important in patient monitoring (other tests may be warranted in some patients, depending on condition; >> = major clinical significance):
- >> Magnesium, serum and
- >> Potassium, serum

(baseline measurements should be taken in patients who are at risk for significant electrolyte disturbances [e.g., diuretic therapy, diarrhea], and patients with low values should be replenished before treatment begins; periodic monitoring of serum electrolytes should be done in patients who are started on diuretics during ziprasidone treatment.)

» QTc interval

(ziprasidone therapy should be discontinued in patients with persistent QTc measurements > 500 msec; occurrence of symptoms of torsade de pointes [e.g., dizziness, palpitations, or syncope] warrant further evaluation with a Holter monitor)

### Side/Adverse Effects

The following side/adverse effects have been selected on the basis of their potential clinical significance (possible signs and symptoms in parentheses where appropriate)-not necessarily inclusive:

### Those indicating need for medical attention

Incidence less frequent

dence less trequer: Tachycardia (fast, pounding, or irregular heartbeat or pulse; palpita. tions)

### Incidence rare

dence rare Cardiac arrhythmias (dizziness; feeling faint or fainting; fast or racing heartbeat; pounding or irregular heartbeat); convulsions (seizures); priapism (persistent, painful erection)-may require surgical intervention; syncope (fainting)

#### Those indicating need for medical attention only if they continue or are bothersome

Asthenia, orthostatic hypotension, anorexia, dry mouth, increased Note: Astrienia, orthostalic reported at a second salivation, arthralgia, anxiety, dizziness, dystonia, hypertonia, somnolence, tremor, rhinitis, rash, and abnormal vision may be dose-related

#### Incidence more frequent

Asthenia (lack or loss of strength; weakness); akathisia (involuntary movements); constipation; diarrhea; dizziness; dyspepsia (acid or sour stomach; belching; heartburn; indigestion; stomach discomfort upset or pain); extrapyramidal syndrome (difficulty in speaking; drooling; loss of balance control; muscle trembling, jerking, or stiff. ness; restlessness; shuffling walk; stiffness of limbs; twisting movements of body; uncontrolled movements, especially of face, neck, and back); nausea; rash-may require antihistamine or steroid therapy or discontinuation of ziprasidone; somnolence (sleepiness or unusual drowsiness); weight gain

#### Incidence less frequent

Abnormal vision (change in vision); anorexia (loss of appetite: weight loss); dry mouth; dystonia (inability to move eyes; increased blinking or spasms of eyelid; sticking out of tongue; trouble in breathing, speaking, or swallowing; uncontrolled twisting movements of neck, trunk, arms, or legs; unusual facial expressions; weakness of arms and legs); fungal dermatitis (red, itchy skin); hypertonia (muscle tightness); myalgia (muscle ache); orthostatic hypotension (feeling faint upon standing); rhinitis (stuffy nose; runny nose; sneezing)

#### Overdose

For more information on the management of overdose or unintentional ingestion, contact a poison control center (see Poison Control Center Listing).

#### **Clinical effects of overdose**

The following effects have been selected on the basis of their potential clinical significance (possible signs and symptoms in parentheses where appropriate) - not necessarily inclusive:

#### Acute effects

Sedation (drowsiness; sleepiness); slurring of speech; transitory hypertension

#### Treatment of overdose

There is no specific antidote for ziprasidone. Treatment is essentially symptomatic and supportive.

To decrease absorption-

Gastric lavage should be considered. Activated charcoal may be administered with a laxative. The risk of aspiration with induced emesis is increased if the patient is obtunded, seizing, or experiencing dystonic movements of the head and neck.

- To enhance elimination
- Ziprasidone is not dialyzable.
- Specific treatment-
  - Maintain an open airway and ensure adequate oxygenation and ventilation.
  - For treatment of severe extrapyramidal symptoms: Administration of anticholinergic agents may be indicated.
  - For treatment of arrhythmias caused by ziprasidone toxicity: Selection of an appropriate antiarrhythmic agent-Use of disopyramide, procainamide, or quinidine may add to ziprasidone toxicity by prolonging the QT interval.
  - For treatment of hypotension or circulatory collapse: Selection of an appropriate sympathomimetic-Beta-adrenergic stimulation properties of epinephrine or dopamine may worsen the hypotension induced by ziprasidone's alpha-adrenergic blockade

Also, the alpha-adrenergic blocking properties of bretylium may add to ziprasidone's effects, producing problematic hypotension.

Monitoring-

Cardiovascular monitoring should begin immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias.

#### 3011 Ziprasidone (Systemic)

#### USP DI

Supportive care-

- Supportive measures such as establishing intravenous lines, hydration, correction of electrolyte imbalance, oxygenation, and support of ventilatory function are essential for maintaining the vital functions of the patient.
- Patients in whom intentional overdose is confirmed or suspected should be referred for psychiatric consultation.

### Patient Consultation

As an aid to patient consultation, refer to Advice for the Patient, Ziprasidone (Systemic).

In providing consultation, consider emphasizing the following selected information (» = major clinical significance):

#### Before using this medication

Conditions affecting use, especially:

Hypersensitivity to ziprasidone.

Other medications, especially QT interval prolongation drugs.

Other medical problems, especially cardiac disease, including recent acute myocardial infarction, bradycardia, cardiac arrhythmias, QT prolongation, uncompensated heart failure; uncorrected electrolyte disorders, including hypokalemia and hypomagnesemia

#### Proper use of this medication

Proper dosing

Swallow capsules whole, do not chew Missed dose: Taking as soon as possible; not taking if almost time for next scheduled dose; not doubling doses

Proper storage

#### Precautions while using this medication

- » Importance of close monitoring by physician
- Obtaining medical attention if fainting, dizziness, fast, racing, pound->> ing, or irregular heartbeat, or other unusual symptoms occur
- Caution while performing activities requiring mental alertness, driving or operating machinery due to potential to impair judgment, thinking, or motor skills
  - Avoid situations involving high temperature or humidity, due to potential interference with ability of the body to adjust to heat

#### Avoid use of alcohol

#### Side/adverse effects

Signs of potential side effects, especially, tachycardia, cardiac arrhythmias, convulsions, priapism, and syncope

### **General Dosing Information**

Ziprasidone should be administered with food.

Dosage adjustments, if needed, should occur at intervals of not less than

2 days, but more appropriately, patients should be observed for improvement for several weeks before upward dose adjustment to ensure use of the lowest effective dose.

Periodically reassess to determine the need for maintenance treatment.

Dispense/prescribe a small number of doses to reduce the risk of attempted overdose.

## **Oral Dosage Forms**

### ZIPRASIDONE CAPSULES

### Usual adult dose

- Schizophrenia-
  - Oral, initial dose 20 mg twice a day, taken with food. Dose may be adjusted, at intervals of not less than 2 days, up to 80 mg twice a day.

#### Usual adult prescribing limits

The safety and efficacy of doses over 100 mg twice a day has not been evaluated in clinical trials, and an increase to a dose above 80 mg twice a day is not recommended.

### Usual pediatric dose

Safety and efficacy have not been established.

### Usual geriatric dose

See Usual adult dose.

#### Usual geriatric prescribing limits See Usual adult prescribing limits.

### Strength(s) usually available

- U.S.
  - 20 mg (Rx) [Geodon (lactose; pregelatinized starch; magnesium stearate)].
  - 40 mg (Rx) [Geodon (lactose; pregelatinized starch; magnesium stearate)].

- 60 mg (Rx) [Geodon (lactose; pregelatinized starch; magnesium stearate)]
- 80 mg (Rx) [Geodon (lactose; pregelatinized starch; magnesium stearate)]

### Packaging and storage

Store between 15 and 30°C (59 and 86 °F).

Revised: 09/06/2002

Developed: 05/30/2001

#### ZOLEDRONIC ACID **Systemic**

VA CLASSIFICATION (Primary): HS 302

Commonly used brand name(s): Zometa.

Note: For a listing of dosage forms and brand names by country availability, see Dosage Forms section(s).

### Category

Bone resorption inhibitor; antihypercalcemic.

#### Indications

Note: Bracketed information in the Indications section refers to uses that are not included in U.S. product labeling.

#### Accepted

- Hypercalcemia, neoplasm-associated (treatment) Zoledronic acid is indicated for the treatment of hypercalcemia of malignancy.
- Multiple myeloma (treatment)1-Zoledronic acid is indicated for the treatment of multiple myeloma
- Metastases, bone (treatment adjunct)-Zoledronic acid is indicated for the treatment of bone metastases from solid tumors in conjunction with standard antineoplastic therapy, including bone metastases from multiple myeloma,1 breast carcinoma,1 prostate carcinoma, and other solid tumors1.
- Note: Prostate cancer should have progressed after treatment with at least one hormonal therapy.

In Canada, this indication is restricted to osteoblastic or mixed osteoblastic/osteolytic bone metastases from prostate cancer.

### Acceptance not established

The safety and efficacy of zoledronic acid in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor related conditions has not been established.

Not included in Canadian product labeling.

### Pharmacology/Pharmacokinetics

#### Physicochemical characteristics

Molecular weight-Molar mass-290.1 g/Mol.

- Solubility-Zoledronic acid is highly soluble in 0.1N sodium hydroxide solution, sparingly soluble in water and 0.1N hydrochloric acid, and practically insoluble in organic solvents.
- pH-The pH of a 0.7% solution of zoledronic acid in water is approximately 2.0

#### Mechanism of action/Effect

Zoledronic acid inhibits bone resorption. The antiresorptive mechanism is not fully understood and several factors are thought to contribute to this action. In vitro, zoledronic acid inhibits osteoclastic activity and induces osteoclast apoptosis. Osteoclastic resorption of mineralized bone and cartilage through its binding to bone is blocked by zoledronic acid. Increased osteoclastic activity and skeletal calcium release induced by various stimulatory factors released by tumors are inhibited by zoledronic acid.

#### Absorption

Area under the plasma concentration versus time curve (AUC) of zoledronic acid was dose proportional from 2 to 16 mg. The accumulation of zoledronic acid measured over three cycles was low, with mean AUC\_{0.24h} ratios for cycles 2 and 3 versus 1 of 1.13  $\pm$  0.30 and 1.16  $\pm$ 0.36, respectively.

#### Protein binding

- Approximately 22% and independent of the concentration.
- Canadian product information states binding to human plasma protein is approximately 56%.

### Terminal Elimination—

146 hours

LETE, THE DAILY DOSE OF DIFLUCAN ONAZOLE) IS THE SAME FOR ORAL (TABLETS ISPENSION) AND INTRAVENOUS ADMINISTRAin general, a loading dose of twice the daily dose is mended on the first day of therapy to result in plasma trations close to steady-state by the second day of

dose of DIFLUCAN for the treatment of infections than vaginal candidiasis should be based on the inorganism and the patient's response to therapy, ant should be continued until clinical parameters or tory tests indicate that active fungal infection has ded. An inadequate period of treatment may lead to remeningitis or recurrent oropharyngeal candidiasis by require maintenance therapy to prevent relapse.

aryngeal candidiasis: The recommended dosage of ICAN for oropharyngeal candidiasis is 200 mg on the followed by 100 mg once daily. Clinical evidence of any fallowed by 100 mg once daily. Clinical evidence of any geal candidiasis generally resolves within several but treatment should be continued for at last the several but treatment should be continued for at least 2 weeks

but treatment should be continued for at least 2 weeks transat the likelihood of relapse. *transat candidiasis:* The recommended dosage of *truCaN* for esophageal candidiasis is 200 mg on the *transat candidiasis* of the source daily. Doses up to 400 mg/ at the used, based on medical judgment of the patient's be used, based on medical judgment of the patient's a may be deterable. Patients with esophageal candidiasis

end be treased by the solution of symptoms. es including candidemia, disseminated candidasis, and manis, optimal therapeutic dosage and duration of disputies, optimite interpretate tosage and duration of stepy have not been established. In open, noncomparative disp of small numbers of patients, doses of up to 400 mg ing have been used.

intry tract infections and peritonitis: For the treatment Candida urinary tract infections and peritonitis, daily of 50-200 mg have been used in open, noncomparative

des of small numbers of patients. reproceed meningitis: The recommended dosage for stiment of acute cryptococcal meningitis is 400 mg on the aday followed by 200 mg once daily. A dosage of 400 mg or daily may be used, based on medical judgment of the stent's response to therapy. The recommended duration of attent for initial therapy of cryptococcal meningitis is si2 weeks after the cerebrospinal fluid becomes culture while The recommended dosage of DIFLUCAN for supmion of relapse of cryptococcal meningitis in patients

ADS is 200 mg once daily. hervaris in patients undergoing bone marrow transplan-ton. The recommended DIFLUCAN daily dosage for the montion of candidiasis of patients undergoing bone marin transplantation is 400 mg, once daily. Patients who are sticpated to have severe granulocytopenia (less than 500 strophils per cu mm) should start DIFLUCAN prophy-us serval days before the anticipated onset of neutrope-

as and continue for 7 days after the neutrophil count rises

box 1000 cells per cu mm. Desige and Administration in Children: De following dose equivalency scheme should generally De following dose equivalency scheme addult nations: Fonds equivalent exposure in pediatric and adult patients:

mg
mg
) mg

the older children may have clearances similar to that of the state of the second seco moumended.

<sup>nce</sup> with DIFLUCAN in neonates is limited to pharokinetic studies in premature newborns. (See CLINI-IL PHARMACOLOGY.) Based on the prolonged half-life In Premature newborns (gestational age 26 to 29 these children, in the first two weeks of life, should the the same dosage (mg/kg) as in older children, but much same dosage (mg/kg) as in older children, but mitored every 72 hours. After the first two weeks, shildren should be dosed once daily. No information miling DIFLUCAN pharmacokinetics in full-term meters is available.

blaryngeal candidiasis: The recommended dosage of LUCAN for oropharyngeal candidiasis in children is set on the first day, followed by 3 mg/kg once daily.

as the likelihood of relapse. 6 mg/kg on the first day, followed by 3 mg/kg once Doses up to 12 mg/kg/day may be used based on med-signed up to 12 mg/kg/day may be used based on medimment of the patient's response to therapy. Patients sphageal candidiasis should be treated for a minithree weeks and for at least 2 weeks following the n of symptoms.

Candida infections: For the treatment of candiand disseminated Candida infections, daily doses of g/day have been used in an open, noncomparative a small number of children.

meningitis: For the treatment of acute crypa maningitis: For the treatment of acute cryp-fort day, followed by 6 mg/kg once daily. A dosage of 4 accompanying stille

duration of treatment for initial merapy of c meningitis is 10-12 weeks after the cerebrospinal fluid becomes culture negative. For suppression of relapse of cryptococcal meningitis in children with AIDS, the recom-mended dose of DIFLUCAN is 6 mg/kg once daily. Dosage In Patients With Impaired Renal Function:

Fluconazole is cleared primarily by renal excretion as unchanged drug. There is no need to adjust single dose ther-apy for vaginal candidiasis because of impaired renal function. In patients with impaired renal function who will receive multiple doses of DIFLUCAN, an initial loading dose of 50 to 400 mg should be given. After the loading dose, the daily dose (according to indication) should be based on the following table:

Creatinine Clearance		Percent of Recommended
(mL/min)		Dose
>50	19	100% 50%
≤50 (no dialysis) Regular dialysis		100% after each dialysis

These are suggested dose adjustments based on pharmacokinetics following administration of multiple doses. Further adjustment may be needed depending upon clinical condition.

When serum creatinine is the only measure of renal function available, the following formula (based on sex, weight, and age of the patient) should be used to estimate the creatinine clearance in adults:

Males:	$\frac{\text{Weight (kg)} \times (140\text{-}age)}{72 \times \text{serum creatinine (mg/100 mL)}}$	
	$72 \times \text{serum creatinine (mg/100 mL)}$	
Females:	0.85  imes above value	

Although the pharmacokinetics of fluconazole has not been studied in children with renal insufficiency, dosage reduction in children with renal insufficiency should parallel that recommended for adults. The following formula may be used to estimate creatinine clearance in children:

linear length or height (cm) Κ× serum creatinine (mg/100 mL) OUT CONTINUES

(Where K=0.55 for children older than 1 year and 0.45 for infants.)

Administration DIFLUCAN may be administered either orally or by intravenous infusion. DIFLUCAN injection has been used safely for up to fourteen days of intravenous therapy. The intrave-nous infusion of DIFLUCAN should be administered at a maximum rate of approximately 200 mg/hour, given as a continuous infusion.

DIFLUCAN injections in glass and Viaflex<sup>®</sup> Plus plastic containers are intended only for intravenous administration using sterile equipment.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Do not use if the solution is cloudy or precipitated or if the seal is not intact.

Directions for Mixing the Oral Suspension Prepare a suspension at time of dispensing as follows: tap bottle until all the powder flows freely. To reconstitute, add 24 mL of distilled water or Purified Water (USP) to fluconazole bottle and shake vigorously to suspend powder. Each bottle will deliver 35 mL of suspension. The concentrations of the reconstituted suspensions are as follows:

Fluconazole Content per	Reconstituted Suspension	
Bottle		
350 mg	10 mg/mL	
1400	40 mg/mL	

1400 mg Note: Shake oral suspension well before using. Store reconstituted suspension between 86°F (30°C) and 41°F (5°C) and discard unused portion after 2 weeks. Protect from freezing. Directions for IV Use of DIFLUCAN in Viaflex® Plus Plastic Containers Do not remove unit from overwrap until ready for use. The

overwrap is a moisture barrier. The inner bag maintains the sterility of the product. CAUTION: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed.

To Open Tear overwrap down side at slit and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. After removing over-

wrap, check for minute If leaks are found, impaired. DO NOT ADD SUPP Preparation for Adm 1. Suspend container 2. Remove plastic pr container.



1/20/13

unit dose blisters. The 150 mg fluconazole tablets are pink and oval shaped, packaged in a single dose unit blister. DIFLUCAN<sup>®</sup> Tablets are supplied as follows: DIFLUCAN<sup>®</sup> 50 mg Tablets: Engraved with "DIFLUCAN"

and "50" on the front and "ROERIG" on the back. Bottles of 30

NDC 0049-3410-30 DIFLUCAN<sup>®</sup> 100 mg Tablets: Engraved with "DIFLUCAN" and "100" on the front and "ROERIG" on the back. Bottles of 30

NDC 0049-3420-30

NDC 0049-3420-30 NDC 0049-3420-30 DIFLUCAN® 150 mg Tablets: Engraved with "DIFLUCAN" and "150" on the front and "ROERIG" on the back. NDC 0049-3500-79 Unit dose package of 1 DIFLUCAN<sup>®</sup> 200 mg Tablets: Engraved with "DIFLUCAN"

and "200" on the front and "ROERIG" on the back. Bottles of 30 NDC 0049-3430-30

Unit dose package of 100 NDC 0049-3430-41 Storage: Store tablets below 86°F (30°C).

DIFLUCAN<sup>®</sup> for Oral Suspension: DIFLUCAN<sup>®</sup> for oral suspension is supplied as an orange-flavored powder to provide 35 mL per bottle as follows:

Fluconazole 350 mg per bottle NDC 0049-3440-19 NDC 0049-3450-19 Fluconazole 1400 mg per bottle Storage: Store dry powder below 86°F (30°C), Store reconstituted suspension between 86°F (30°C) and 41°F (5°C) and discard unused portion after 2 weeks. Protect from freezing. DIFLUCAN<sup>®</sup> Injections: DIFLUCAN<sup>®</sup> injections for intravenous infusion administration are formulated as sterile sensors infusion administration are infundated as source iso-osmotic solutions containing 2 mg/mL of fluconazole. They are supplied in glass bottles or in Viaflex<sup>®</sup> Plus plastic containers containing volumes of 100 mL or 200 mL afford-ing decreased 200 merced fluconary locations in the ing doses of 200 mg and 400 mg of fluconazole, respectively. DIFLUCAN<sup>®</sup> injections in Viaflex<sup>®</sup> Plus plastic containers are available in both sodium chloride and dextrose diluents. DIFLUCAN<sup>®</sup> Injections in Glass Bottles:

NDC 0049-3371-26 Fluconazole in Sodium Chloride Diluent 200 mg/100 mL × 6

NDC 0049-3372-26 Fluconazole in Sodium Chloride Diluent 400 mg/200 mL × 6

Storage: Store between 86°F (30°C) and 41°F (5°C). Pro-

tect from freezing. DIFLUCAN<sup>®</sup> Injections in Viaflex<sup>®</sup> Plus Plastic Containers: NDC 0049-3435-26 Fluconazole in Sodium Chloride Diluent 200 mg/100 mL  $\times$  6 NDC 0049-3436-26 Fluconazole in Sodium Chloride Diluent

400 mg/200 mL  $\times$  6 NDC 0049-3437-26 Fluconazole in Dextrose Diluent

200 mg/100 mL × 6 NDC 0049-3438-26 Fluconazole in Dextrose Diluent

400 mg/200 mL  $\times$  6 Storage: Store between 77°F (25°C) and 41°F (5°C). Brief exposure up to 104°F (40°C) does not adversely affect the product. Protect from freezing. ©2003 PFIZER INC

Rx only Pfizer Roerig Division of Pfizer Inc, NY, NY 10017 70-4526-00-8

**Revised June 2003** Shown in Product Identification Guide, page 329

GEODON<sup>®</sup> [ø∂.∂.dðn] [gē-ō-dōn] (ziprasidone HCI) GEODON<sup>®</sup> for Injection (ziprasidone mesylate) FOR IM USE ONLY and the party

DESCRIPTION

GEODON<sup>®</sup> is available as GEODON Capsules (ziprasidone hydrochloride) for oral administration and as GEODON for Injection (ziprasidone mesylate) for intramuscular injection. Ziprasidone is an antipsychotic agent that is chemically unrelated to phenothiazine or butyrophenone antipsychotic agents. It has a molecular weight of 412.94 (free base), with the following chemical name: 5-[2-[4-(1,2-benzisothiazol-3-y])-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2one. The empirical formula of  $C_{21}H_{21}CIN_4OS$  (free base of ziprasidone) represents the following structural formula:

=0 C

GEODON Capsules contain a monohydrochloride, monohy-drate salt of ziprasidone. Chemically, ziprasidone hydro-chloride monohydrate is 5-[2-[4-(1,2-benzisothiazol-3-y])-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one, monohydrochloride, monohydrate. The empirical formula is  $C_{21}H_{21}CIN_4OS \cdot HCl \cdot H_2O$  and its molecular weight is 467.42. Ziprasidone hydrochloride monohydrate is a white to slightly pink powder. minh

GEODON Capsules are supplied for oral administration in 20 mg (blue/white), 40 mg (blue/blue), 60 mg (white/white), and 80 mg (blue/white) capsules. GEODON Capsules contain ziprasidone hydrochloride monohydrate, lactose, pregelatinized starch, and magnesium stearate.

GEODON for Injection contains a lyophilized form of ziprasidone mosylate trihydrate. Chemically, ziprasidone mesylate trihydrate is 5-[2-[4-(1,2-benzisothiazol.3-y])-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one, methanesulfonate, trihydrate. The empirical formula is  $C_{21}H_{21}ClN_4OS$   $\bullet$   $CH_3SO_2H$   $\bullet$   $3H_2O$  and its molecular weight is 563.09.

GEODON for Injection is available in a single dose vial as ziprasidone mesylate (20 mg ziprasidone/mL when reconstituted according to label instructions - see Preparation for Administration) for intramuscular administration. Each mL of ziprasidone mesylate for injection (when reconstituted) contains 20 mg of ziprasidone and 4.7 mg of methanesulfonic acid solubilized by 294 mg of sulfobutylether  $\beta$ -cyclodextrin sodium (SBECD).

### CLINICAL PHARMACOLOGY

### Pharmacodynamics

Ziprasidone exhibited high in vitro binding affinity for the dopamine D<sub>2</sub> and D<sub>3</sub>, the serotonin 5HT<sub>2A</sub>, 5HT<sub>2C</sub>, 5HT<sub>1A</sub>, 5HT<sub>1D</sub>, and  $\alpha_1$ -adrenergic receptors (K<sub>1</sub> s of 4.8, 7.2, 0.4, 1.3, 3.4, 2, and 10 nM, respectively), and moderate affinity S.a, 2, and 10 hav, respectively, and nontrare many for the histamine H<sub>1</sub> receptor (K<sub>1</sub>=47 nM). Ziprasidone functioned as an antagonist at the D<sub>2</sub>, 5HT<sub>2A</sub>, and 5HT<sub>1D</sub> receptors, and as an agonist at the 5HT<sub>1A</sub> receptor. Ziprasidone inhibited synaptic reuptake of serotonin and norepinephrine. No appreciable affinity was exhibited for other receptor/binding sites tested, including the cholinergic muscarinic receptor (IC50 >1 µM).

The mechanism of action of ziprasidone, as with other drugs having efficacy in schizophrenia, is unknown. However, it has been proposed that this drug's efficacy in schizophrenia is mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5HT2) antagonism. Antagonism at receptors other than dopamine and 5HT<sub>2</sub> with similar recep-tor affinities may explain some of the other therapeutic and side effects of ziprasidone.

Ziprasidone's antagonism of histamine H1 receptors may explain the somnolence observed with this drug.

Ziprasidone's antagonism of  $\alpha_1$ -adrenergic receptors may explain the orthostatic hypotension observed with this drug. **Oral Pharmacokinetics** 

Ziprasidone's activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range. Steady-state concentrations are achieved within one to three days of dosing. The mean apparent systemic clearance is 7.5 mL/min/kg Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes.

Absorption: Ziprasidone is well absorbed after oral administration, reaching peak plasma concentrations in 6 to 8 hours. The absolute bioavailability of a 20 mg dose under fed conditions is approximately 60%. The absorption of ziprasidone is increased up to two-fold in the presence of food.

Distribution: Ziprasidone has a mean apparent volume of distribution of 1.5 L/kg. It is greater than 99% bound to plasma proteins, binding primarily to albumin and  $\alpha_1$ -acid glycoprotein. The *in vitro* plasma protein binding of ziprasidone was not altered by warfarin or propranolol, two highly protein-bound drugs, nor did ziprasidone alter the binding of these drugs in human plasma. Thus, the potential for drug interactions with ziprasidone due to displacement is minimal.

Metabolism and Elimination: Ziprasidone is extensively metabolized after oral administration with only a small amount excreted in the urine (<1%) or feces (<4%) as unchanged drug, Ziprasidone is primarily cleared via three metabolic routes to yield four major circulating metabolites, benzisothiazole (BITP) sulphoxide, BITP-sulphone, ziprasidone sulphoxide, and S-methylmetabolites. dihydroziprasidone. Approximately 20% of the dose is excreted in the urine, with approximately 66% being eliminated in the feces. Unchanged ziprasidone represents about 44% of total drug-related material in serum. In vitro studies using human liver subcellular fractions indicate that Smethyl-dihydroziprasidone is generated in two steps. The data indicate that the reduction reaction is mediated by aldehyde oxidase and the subsequent methylation is mediated by thiol methyltransferase. In vitro studies using human liver microsomes and recombinant enzymes indicate that CYP3A4 is the major CYP contributing to the oxidative metabolism of ziprasidone. CYP1A2 may contribute to a much lesser extent. Based on in vivo abundance of excretory metabolites, less than one-third of ziprasidone metabolic clearance is mediated by cytochrome P450 catalyzed oxidation and approximately two-thirds via reduction by aldehyde oxidase. There are no known clinically relevant inhibitors or inducers of aldehyde oxidase.

Information will be superseded by supplements and subsequent addition

a commuter opproaches occur at approximately 60 minutes post-dose or earlier and the mean half-life (T<sub>16</sub>) ranges from two to five hours. Exposure increases in a dose-related manner and following three days of intramuscular dosing, little accumulation is observed.

Metabolism and Elimination: Although the metabolism and elimination of IM ziprasidone have not been systematically evaluated, the intramuscular route of administration would not be expected to alter the metabolic pathways. **Special Populations** 

Age and Gender Effects-In a multiple-dose (8 days of treatment) study involving 32 subjects, there was no difference in the pharmacokinetics of ziprasidone between men and women or between elderly (>65 years) and young (18 to 45 years) subjects. Additionally, population pharmacokinetic evaluation of patients in controlled trials has revealed no evidence of clinically significant age or gender-related differences in the pharmacokinetics of ziprasidone. Dosage modifications for age or gender are, therefore, not recommended.

Ziprasidone intramuscular has not been systematically evaluated in elderly patients (65 years and over). Race-No specific pharmacokinetic study was conducted

to investigate the effects of race. Population pharmacokinetic evaluation has revealed no evidence of clinically significant race-related differences in the pharmacokinetics of ziprasidone. Dosage modifications for race are, therefore, not recommended.

Smoking-Based on in vitro studies utilizing human liver enzymes, ziprasidone is not a substrate for CYP1A2; smoking should therefore not have an effect on the pharmacokinetics of ziprasidone. Consistent with these in vitro results, population pharmacokinetic evaluation has not revealed any significant pharmacokinetic differences between smokers and nonsmokers.

Renal Impairment-Because ziprasidone is highly metabolized, with less than 1% of the drug excreted unchanged, renal impairment alone is unlikely to have a major impact on the pharmacokinetics of ziprasidone. The pharmacokinetics of ziprasidone following 8 days of 20 mg BID dosing were similar among subjects with varying degrees of renal impairment (n=27), and subjects with normal renal function, indicating that dosage adjustment based upon the degree of renal impairment is not required. Ziprasidone is not removed by hemodialysis.

Hepatic Impairment-As ziprasidone is cleared substantially by the liver, the presence of hepatic impairment would be expected to increase the AUC of ziprasidone; a multipledose study at 20 mg BID for 5 days in subjects (n=13) with elinically significant (Childs-Pugh Class A and B) cirrhosis revealed an increase in AUC<sub>0-12</sub> of 13% and 34% in Childs-Pugh Class A and B, respectively, compared to a matched control group (n=14). A half-life of 7.1 hours was observed in subjects with cirrhosis compared to 4.8 hours in the control group.

Intramuscular ziprasidone has not been systematically evaluated in elderly patients or in patients with hepatic or renal impairment. As the cyclodextrin excipient is cleared by renal filtration, ziprasidone intramuscular should be administered with caution to patients with impaired renal function.

#### **Drug-Drug Interactions**

An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes. In vivo studies have revealed no effect of ziprasidone on the pharmacokinetics of dextromethorphan, estrogen, progesterone, or lithium (see Drug Interactions under PRECAUTIONS).

In vivo studies have revealed an approximately 35% decrease in ziprasidone AUC by concomitantly administered carbamazepine, an approximately 35-40% increase in ziprasidone AUC by concomitantly administered ketoconazole, but no effect on ziprasidone's pharmacokinetics by cimetidine or antacid (see Drug Interactions, under PRECAUTIONS). **Clinical Trials** 

The efficacy of oral ziprasidone in the treatment of schizophrenia was evaluated in 5 placebo-controlled studies, 4 short-term (4- and 6-week) trials and one long-term (52week) trial. All trials were in inpatients, most of whom met DSM III-R criteria for schizophrenia. Each study included 2 to 3 fixed doses of ziprasidone as well as placebo. Four of the 5 trials were able to distinguish ziprasidone from placebo; one short-term study did not. Although a single fixed-dose haloperidol arm was included as a comparative treatment in one of the three short-term trials, this single study was inadequate to provide a reliable and valid comparison of ziprasidone and haloperidol.

Several instruments were used for assessing psychiatric signs and symptoms in these studies. The Brief Psychiatric Rating Scale (BPRS) and the Positive and Negative Syndrome Scale (PANSS) are both multi-item inventories of general psychopathology usually used to evaluate the effects of drug treatment in schizophrenia. The BPRS psychosis cluster (conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) is considered a particularly useful subset for assessing actively psychotic schizophrenic patients. A second widely Systemic Bioavailability of The tique introduced as the second widely used assessment, the Clinical Global Impression (CGD), represent the value of the value of

sessing Negative Symptoms (SANS) was on plane sessing negative symptoms in one trial. The sessing the results of the oral ziprasidone trials follow (1) In a 4-week, placebo-controlled trial (new) 2 fixed doses of ziprasidone (20 and 60 mg Bil) on eebo, only the 60 mg BID dose was superior to the BPRS total score and the CGI several to which where the construction of the second several to history on the second several to be a several to history on the several to be a several to be a several to history on the several to be a several to be a several to history on the several to be a several to be a several to history on the several to be a several to be a several to history on the several to be a several to be a several to history on the several to be a several to be a several to history on the several to be a several to be a several to history on the several to be a several to be a several to history on the several to be a several to be a several to be a several to history of the several to be a several to be a several to be a several to history of the several to be a sev

cebo, only and the BPRS total score and the CC1 Severity black higher dose group was not superior to placebo on the SANS. (2) In a 6-week, placebo-controlled trial (n=302) control on the severity black (2) In a 6-week, placebo-controlled trial (n=302) control on the severity black (2) In a 6-week, placebo-controlled trial (n=302) control on the severity black (2) In a 6-week, placebo-controlled trial (n=302) control on the severity black (2) In a 6-week, placebo-controlled trial (n=302) control on the severity black (2) In a 6-week, placebo-controlled trial (n=302) control on the severity black (2) In a 6-week, placebo-controlled trial (n=302) control on the severity black (2) In a 6-week, placebo-controlled trial (n=302) control on the severity black (2) In a 6-week, placebo-controlled trial (n=302) control on the severity black (2) In a 6-week, placebo-controlled trial (n=302) control on the severity black (2) In a 6-week, placebo-controlled trial (n=302) control on the severity black (2) In a 6-week (n=302) control on the severity black (2) In a 6-week (n=302) control on the severity black (3) In a 6-week (n=302) control on the severity black (4) In a 6-week (n=302) control on the severity black (4) In a 6-week (n=302) control on the severity black (4) In a 6-week (n=302) control on the severity black (4) In a 6-week (n=302) control on the severity black (4) In a 6-week (n=302) control on the severity black (4) In a 6-week (n=302) control on the severity black (4) In a 6-week (n=302) control on the severity black (4) In a 6-week (n=302) control on the severity black (4) In a 6-week (n=302) control on the severity black (4) In a 6-week (n=302) control on the severity black (4) In a 6-week (n=302) control on the severity black (4) In a 6-week (n=302) control on the severity black (4) In a 6-week (n=302) control on the severity black (4) In a 6-week (n=302) control on the severity black (4) In a 6-week (n=302) control on the severity black (4) In a 6-week (n=302) control on the severity black (4) In a 6-week (1

psychosts where 1 = 0 and 80 mg BD (2) in a 6-week, placebo-controlled that  $M = 30(2) c_{\text{transverse}} c_{\text{t$ 2 fixed doses of ziprasiuone (as superior to glacebo, both dose groups were superior to glacebo were superior to glacebo were superior to glacebo cebo, both dose groups were superior to placebo, BPRS total score, the BPRS psychosis cluster, the or PRS total score, the PANSS total and negative to verity score and the PANSS total and negative to Although 80 mg BID had a numericall. verity score and the route had a numerically scores. Although 80 mg BID had a numerically bit the difference was scores. Although 80 mg bill, the difference was not study a effect than 40 mg BID, the difference was not study a

significant. (3) In a 6-week, placebo-controlled trial (n=419)  $c_{00}$  (3) In a 6-week, placeou control (20, 60, and 100 mg bing)
 3 fixed doses of ziprasidone (20, 60, and 100 mg bing)
 3 fixed doses groups were superior (a, a) the PANSS total score, the Brass choice, the Brass choice choice and the CGI severity score. Only the total choice chosis cluster, and the total action of the life the life bill dose group was superior to placebo on the PANSS bill dose group was no clear evidence. BID dose group was superior to plant of the PANSS a ative subscale score. There was no clear evidence for a d ative subscale score. There was a subscale for a data response relationship within the 20 mg BID to 100 mg bill

 dose range.
 (4) In a 4-week, placebo-controlled trial (n=200) company.
 (4) In a 4-week, placebo-controlled trial (n=200) company. (4) In a 4-week, placeoo-construction and 40 mg BID), here 3 fixed doses of ziprasidone (5, 20, and 40 mg BID), here statistically superior to bland. 3 fixed doses of ziprasuone (a), superior to placebook the dose groups was statistically superior to placebook outcome of interest. (5) A study was conducted in chronic, symptomatically us investigates (n=294) randomized a

(5) A study was conducted at the second statically at ble schizophrenic inpatients (n=294) randomized to 3 functions (200, 40, or 80 mg BID) or statically at the second statical static statical statical statical statical statical statical statica ble schizophrenic inpatients (a 80 m BID) or placebo a doses of ziprasidone (20, 40, or 80 m BID) or placebo followed for 52 weeks. Fatterne north strength on impor-ing psychotic relapse," defined as CGI-improvement score, (much worse or very much worse) and/or scores ≥6 (much worse of very moderately severe) on the hostility or uncooperative. items of the PANSS on two consecutive days, Ziprasid items of the PAND on two tangents of the contract was significantly superior to placebo in both time to relate and rate of relapse, with no significant difference betw the different dose groups.

based on age and race. Examination of population subbased on gender did not reveal any differential responsive

The efficacy of inframuscular ziprasidone in the mann ment of agitated schizophrenic patients was established in two short-term, double-blind trials of schizophrenic subject who were considered by the investigators to be "acutely ar itated" and in need of IM antipsychotic medication. In add tion, patients were required to have a score of 3 or more as at least 3 of the following items of the PANSS: anxiety, ten sion, hostility and excitement. Efficacy was evaluated by analysis of the area under the curve (AUC) of the Behav ioural Activity Rating Scale (BARS) and Clinical Global Impression (CGI) severity rating. The BARS is a seven point scale with scores ranging from 1 (difficult or unable to rouse) to 7 (violent, requires restraint). Patients' scores on the BARS at baseline were mostly 5 (signs of overt activity [physical or verbal], calms down with instructions) and a determined by investigators, exhibited a degree of agitation that warranted intramuscular therapy. There were few pa tients with a rating higher than 5 on the BARS, as the more severely agitated patients were generally unable to provide informed consent for participation in pre-marketing clinical trials.

Both studies compared higher doses of ziprasidone intro muscular with a 2 mg control dose. In one study, the high dose was 20 mg, which could be given up to 4 times in the 24 hours of the study, at interdose intervals of no less than hours. In the other study, the higher dose was 10 mg, which could be given up to 4 times in the 24 hours of the study, at interdose intervals of no less than 2 hours.

The results of the intramuscular ziprasidone trials follow (1) In a one-day, double-blind, randomized trial (n=79) in volving doses of ziprasidone intramuscular of 20 mg or 2 mg us to OD. 2 mg, up to QID, ziprasidone intramuscular 20 mg was sta tistically superior to ziprasidone intramuscular 2 mg, as a sessed by AUC of the BARS at 0 to 4 hours, and by COI

severity at 4 hours and study endpoint. (2) In another one-day, double-blind, randomized tria (n=117) involving doses of ziprasidone intramuscular of 10 mg or 2 mg up to CUD 10 mg or 2 mg, up to QID, ziprasidone intramuscular 10 ms was statistically superior to ziprasidone intramuscular 2 mg, as assessed by AUC of the BARS at 0 to 2 hours, but not by CGI savority. not by CGI severity.

### INDICATIONS AND USAGE

Ziprasidone is indicated for the treatment of schizophre When deciding among the alternative treatments available for this condition, the second secon for this condition, the prescriber should consider the indict of ziprasidone's greater of ziprasidone's greater capacity to prolong the QT/QT to terval compared to average the capacity to prolong the QT/QT to the second to average to the second to be average to the second to the second to be average to the second to the secon terval compared to several other antipsycholic drugs (aw WARNINGS). Prolongation of the antipsycholic drugs (aw WARNINGS). Prolongation of the QTc interval is as ated in some other drugs with the ability to cause torsade de pointes-type arrhythmic pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachyconilia ventricular tachycardia, and sudden death. In many c this would lead to the conclusion that other drugs should be tried first. Whether vieweed of the drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet

tients (see CLINICAL PHARMACOLOGY).

stable schizophrenic inpatients, GEODON was to delay the time to and rate of relapse. The who elects to use GEODON for extended periods dically re-evaluate the long-term usefulness of of the individual patient.

intramuscular is indicated for the treatment of ion in schizophrenic patients for whom treat-distinguishing and the schizophrenic patients for whom treat-singuishing and the schizophrenic antipsychotic medication for rapid control of the psychomotor agitation" is defined in DSM-IV as motor activity associated with a feeling of inner schizophrenic patients experiencing agitation ofbehaviors that interfere with their diagnosis the the use of intramuscular antipsychotic medicaand the second s d intramuscular ziprasidono for acute agitation in drenia was established in single-day controlled trihisophrenic inpatients (see CLINICAL PHARMA-(GT). Since there is no experience regarding the donate is no experience regarding the administering ziprasidone intramuscular to schizoof patients already taking oral ziprasidone, the prac-

# WTRAINDICATIONS

BID acela Jacela Jacela

mg Bij

mparini none (

on any

illy sta 3 fixed

bu and

mpend.

icore of

04 PO

Venta

Bidnine

elapse

tween

ibset.

ibset

Isive

aage. ed in

jects

y ag. Iddi-

e on ten-by

lav.

In).

int to

on

ity as on u.

frolongation folony in the known accessed to prolongation of the QT and the known association of fatal arrhythmias of prolongation by some other drugs, ziprasidone is indicated in patients with a known history of QT protion (including congenital long QT syndrome), with reacute myocardial infarction, or with uncompensated failure (see WARNINGS).

armacokinetic/pharmacodynamic studies between regione and other drugs that prolong the QT interval wher drugs that prolong the QT interval cannot be ex-Therefore, ziprasidone should not be given with wilde, sotalol, quinidine, other Class Ia and III anti-typhnics, mesoridazine, thioridazine, chlorpromazine, pridol, pimozide, sparfloxacin, gatifloxacin, moxifloxahalofantrine, mefloquine, pentamidine, arsenic trioxide, omethadyl acetate, dolasetron mesylate, probucol or tac-Inns. Ziprasidone is also contraindicated with drugs that un demonstrated QT prolongation as one of their pharmadynamic effects and have this effect described in the full cribing information as a contraindication or a boxed or Isd warning (see WARNINGS). Hpersensitivity

innsidene is contraindicated in individuals with a known mersensitivity to the product.

THE STORE

TARNINGS at Prolongation and Risk of Sudden Death

Tensidone use should be avoided in combination with after drugs that are known to prolong the QTc interval (see CONTRAINDICATIONS; and see Drug Interactions unter FRECAUTIONS). Additionally, clinicians should be alen to the identification of other drugs that have tem consistently observed to prolong the QTc interval. Such drugs should not be prescribed with ziprasidone. forasidone should also be avoided in patients with con-Initial long QT syndrome and in patients with a history of ardiac arrhythmias (see CONTRAINDICATIONS).

A study directly comparing the QT/QTc prolonging effect of and ziprasidone with several other drugs effective in the tratment of schizophrenia was conducted in patient volmeers. In the first phase of the trial, ECGs were obtained It the time of maximum plasma concentration when the trug was administered alone. In the second phase of the Mail ECGs were obtained at the time of maximum plasma <sup>oncentration</sup> while the drug was co-administered with an hibitor of the CYP4503A4 metabolism of the drug.

the first phase of the study, the mean change in QTc <sup>fom</sup> baseline was calculated for each drug, using a umple-based correction that removes the effect of heart the on the QT interval. The mean increase in QTc from baseline for ziprasidone ranged from approximately 9 to 14 <sup>thee</sup> greater than for four of the comparator drugs (risperdone, olanzapine, quetiapine, and haloperidol), but was pproximately 14 msec less than the prolongation served for thioridazine.

the second phase of the study, the effect of ziprasidone a Crc length was not augmented by the presence of a etabolic inhibitor (ketoconazole 200 mg BID).

Placebo-controlled trials, oral ziprasidone increased the of response to placebo by approximately to be approxim In msec at the highest recommended daily dose of 160 mg. i clinical trials with oral ziprasidone, the electrocardiona of 2/2988 (0.06%) patients who received GEODON 1/440 (0.23%) patients who received placebo revealed Ofe intervals exceeding the potentially clinically relevant threshold of 500 msec. In the ziprasidone-treated patients, heither case suggested a role of ziprasidone. One patient a history of prolonged QTc and a screening measurehent of 489 msec; QTc was 503 msec during ziprasidone beatment. The other patient had a QTc of 391 msec at the nd of treatment with ziprasidone and upon switching to Monidazine experienced QTc measurements of 518 and tag msec.

ione drugs that prolong the Orthogran Bryar have have toolated with the occurrence of torsade de pointes and with hith sudden unexplained death. The relationship of QT

creases (20 msec and greater) but it is possible that smaller QT/QTc prolongations may also increase risk, or increase it in susceptible individuals, such as those with hypokalemia, hypomagnesemia, or genetic predisposition. Although torsade de pointes has not been observed in association with the use of ziprasidone at recommended doses in premarketing studies, experience is too limited to rule out an increased risk.

A study evaluating the QT/QTc prolonging effect of intramuscular ziprasidone, with intramuscular haloperidol as a control, was conducted in patient volunteers. In the trial, ECGs were obtained at the time of maximum plasma concentration following two injections of ziprasidone (20 mg then 30 mg) or haloperidol (7.5 mg then 10 mg) given four hours apart. Note that a 30 mg dose of intramuscular ziprasidone is 50% higher than the recommended therapeutic dose. The mean change in QTc from baseline was calculated for each drug, using a sample-based correction that removes the effect of heart rate on the QT interval. The mean increase in QTc from baseline for ziprasidone was 4.6 msec following the first injection and 12.8 msec following the second injection. The mean increase in QTc from baseline for haloperidol was 6.0 msec following the first injection and 14.7 msec following the second injection. In this study, no patients had a QTc interval exceeding 500 msec.

As with other antipsychotic drugs and placebo, sudden unexplained deaths have been reported in patients taking ziprasidone at recommended doses. The premarketing experience for ziprasidone did not reveal an excess risk of mortality for ziprasidone compared to other antipsychotic drugs or placebo, but the extent of exposure was limited, especially for the drugs used as active controls and placebo. Nevertheless, ziprasidone's larger prolongation of QTc length compared to several other antipsychotic drugs raises the possibility that the risk of sudden death may be greater for ziprasidone than for other available drugs for treating schizophrenia. This possibility needs to be considered in deciding among alternative drug products (see IN-DICATIONS AND USAGE).

Certain circumstances may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval.

It is recommended that patients being considered for ziprasidone treatment who are at risk for significant electrolyte disturbances, hypokalemia in particular, have baseline serum potassium and magnesium measurements. Hypokalemia (and/or hypomagnesemia) may increase the risk of QT prolongation and arrhythmia. Hypokalemia may result from diuretic therapy, diarrhea, and other causes. Patients with low serum potassium and/or magnesium should be repleted with those electrolytes before proceeding with treatment. It is essential to periodically monitor serum electrolytes in patients for whom diuretic therapy is introduced during ziprasidone treatment. Persistently prolonged QTc intervals may also increase the risk of further prolongation and arrhythmia, but it is not clear that routine screening ECG measures are effective in detecting such patients. Rather, ziprasidone should be avoided in patients with histories of significant cardiovascular illness, e.g., QT prolongation, recent acute myocardial infarction, uncompensated heart failure, or cardiac arrhythmia. Ziprasidone should be discontinued in patients who are found to have persistent QTc measurements >500 msec.

For patients taking ziprasidone who experience symptoms that could indicate the occurrence of torsade de pointes, e.g., dizziness, palpitations, or syncope, the prescriber should initiate further evaluation, e.g., Holter monitoring may be useful.

#### Neuroleptic Malignant Syndrome (NMS)

A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to exclude cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology.

The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for BS JPS Filed 11/26/13 Page 3 of Freedment 171-6

covery from NMS, the potential reintroduction of drug ther-

carefully monitored, since recurrences of NMS have been reported Tardive Dyskinesia

A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients undergoing treatment with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.

The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.

There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is with-drawn. Antipsychotic treatment itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.

Given these considerations, ziprasidone should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

If signs and symptoms of tardive dyskinesia appear in a patient on ziprasidone, drug discontinuation should be considered. However, some patients may require treatment with ziprasidone despite the presence of the syndrome. Hyperglycemia and Diabetes Mellitus

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. There have been few reports of hyperglycemia or diabetes in patients treated with GEODON. Although fewer patients have been treated with GEODON, it is not known if this more limited experience is the sole reason for the paucity of such reports. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies, which did not include GEODON, suggest an increased risk of treatment-emergent hyperglycemiarelated adverse events in patients treated with the atypical antipsychotics included in these studies. Because GEODON was not marketed at the time these studies were performed, it is not known if GEODON is associated with this increased risk. Precise risk estimates for hyperglycemia-related adverse events in patients treated with atypical antipsychotics are not available.

Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug.

#### PRECAUTIONS Historice and the smaller General

Rash-In premarketing trials with ziprasidone, about 5% of patients developed rash and/or urticaria, with discontinuation of treatment in about one-sixth of these cases. The occurrence of rash was related to dose of ziprasidone, although the finding might also be explained by the longer exposure time in the higher dose patients. Several patients with rash had signs and symptoms of associated systemic illness, e.g., elevated WBCs. Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these events were reported to recover completely. Upon appearance of rash for which an alternative etiology cannot be identified, ziprasidone should be

Orthostatic Hypotension-Ziprasidone may induce orthostatic hypotension associated with dizziness, tachycardia, and, in some patients, syncope, especially during the initial dose-titration period, probably reflecting its arrangemergic antagonist properties. Syncope was reported in 0.6% of the patients treated with ziprasidone.

Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications).

Seizures-During clinical trials, seizures occurred in 0.4% of patients treated with ziprasidone. There were confounding factors that may have contributed to the occurrence of seizures in many of these cases. As with other antipsychotic drugs, ziprasidone should be used cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold, e.g., Alzheimer's dementia. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older.

Hyperprolactinemia—As with other drugs that antagonize dopamine D2 receptors, ziprasidone elevates prolactin levels in humans. Increased prolactin levels were also observed in animal studies with this compound, and were associated with an increase in mammary gland neoplasia in mice; a similar effect was not observed in rats (see Carcinogenesis). Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with prolactin-elevating compounds, the clinical significance of elevated serum prolactin levels is unknown for most patients. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too, limited to be conclusive at this time.

Potential for Cognitive and Motor Impairment-Somnolence was a commonly reported adverse event in patients treated with ziprasidone. In the 4- and 6-week placebocontrolled trials, somnolence was reported in 14% of pa-tients on ziprasidone compared to 7% of placebo patients. Somnolence led to discontinuation in 0.3% of patients in short-term clinical trials. Since ziprasidone has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about performing activities requiring mental alertness, such as operating a motor vehicle (including automobiles) or operating hazardous machinery until they are reasonably certain that ziprasidone therapy does not affect them adversely.

Priapism-One case of priapism was reported in the premarketing database. While the relationship of the event to ziprasidone use has not been established, other drugs with alpha-adrenergic blocking effects have been reported to induce priapism, and it is possible that ziprasidone may share this capacity. Severe priapism may require surgical intervention.

Body Temperature Regulation-Although not reported with ziprasidone in premarketing trials, disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing ziprasidone for patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anti-cholinergic activity, or being subject to dehydration.

Dysphagia-Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia. Ziprasidone and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

Suicide-The possibility of a suicide attempt is inherent in psychotic illness and close supervision of high-risk patients should accompany drug therapy. Prescriptions for ziprasidone should be written for the smallest quantity of capsules consistent with good patient management in order to reduce the risk of overdose.

Use in Patients with Concomitant Illness-Clinical experience with ziprasidone in patients with certain concomitant systemic illnesses (see Renal Impairment and Hepatic Im-pairment under CLINICAL PHARMACOLOGY, Special Populations) is limited.

Ziprasidone has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical studies. Because of the risk of QTc prolongation and orthostatic hypotension with ziprasidone, caution should be observed in cardiac patients (see QTc Prolongation under WARNINGS and Orthostatic Hypotension under PRECAUTIONS). Information for Patients

Please refer to the patient package insert. To assure safe and effective use of GEODON, the information and instructions provided in the partie in the partie of the tion cussed with patients

are at risk of significant electrolyte disturbances should have baseline serum potassium and magnesium measurements. Low serum potassium and magnesium should be repleted before proceeding with treatment. Patients who are started on diuretics during ziprasidone therapy need periodic monitoring of serum potassium and magnesium. Ziprasidone should be discontinued in patients who are found to have persistent QTc measurements >500 msec (see WARNINGS). and sentences in the second

#### Drug Interactions

Drug-drug interactions can be pharmacodynamic (combined pharmacologic effects) or pharmacokinetic (alteration of plasma levels). The risks of using ziprasidone in combination with other drugs have been evaluated as described below. All interactions studies have been conducted with oral ziprasidone. Based upon the pharmacodynamic and pharmacokinetic profile of ziprasidone, possible interactions could be anticipated: Pharmacodynamic Interactions

(1) Ziprasidone should not be used with any drug that prolongs the QT interval (see CONTRAINDICA-TIONS).

(2) Given the primary CNS effects of ziprasidone, caution should be used when it is taken in combination with other centrally acting drugs.

(3) Because of its potential for inducing hypotension. ziprasidone may enhance the effects of certain antihy-

pertensive agents. (4) Ziprasidone may antagonize the effects of levodopa and dopamine agonists.

US 101 SH Pharmacokinetic Interactions idition of the steps The Effect of Other Drugs on Ziprasidone

Carbamazepine -- Carbamazepine is an inducer of CYP3A4; administration of 200 mg BID for 21 days resulted in a de-crease of approximately 35% in the AUC of ziprasidone. This effect may be greater when higher doses of carbamazepine are administered. Ketoconazole–Ketoconazole, a potent inhibitor of CYP3A4,

at a dose of 400 mg QD for 5 days, increased the AUC and Cmax of ziprasidone by about 35-40%. Other inhibitors of CYP3A4 would be expected to have similar effects. Cimetidine—Cimetidine at a dose of 800 mg QD for 2 days

did not affect ziprasidone pharmacokinetics. Antacid—The coadministration of 30 mL of Maalox<sup>®</sup> with

ziprasidone did not affect the pharmacokinetics of ziprasidone. In addition, population pharmacokinetic analysis of schizo-

phrenic patients enrolled in controlled clinical trials has not revealed evidence of any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam.

Effect of Ziprasidone on Other Drugs

In vitro studies revealed little potential for ziprasidone to interfere with the metabolism of drugs cleared primarily by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, and little potential for drug interactions with ziprasidone due to displacement (see CLINICAL PHARMACOLOGY, Pharmacokinetics).

Lithium-Ziprasidone at a dose of 40 mg BID administered concomitantly with lithium at a dose of 450 mg BID for 7 days did not affect the steady-state level or renal clearance of lithium. Oral Contraceptives-Ziprasidone at a dose of 20 mg BID

did not affect the pharmacokinetics of concomitantly administered oral contraceptives, ethinyl estradiol (0.03 mg) and levonorgestrel (0.15 mg). Dextromethorphan—Consistent with in vitro results, a

study in normal healthy volunteers showed that ziprasidone not alter the metabolism of dextromethorphan, a CYP2D6 model substrate, to its major metabolite, dextrorphan. There was no statistically significant change in the urinary dextromethorphan/dextrorphan ratio.

Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis—Lifetime carcinogenicity studies were con-ducted with ziprasidone in Long Evans rats and CD-1 mice. Ziprasidone was administered for 24 months in the diet at doses of 2, 6, or 12 mg/kg/day to rats, and 50, 100, or 200 mg/kg/day to mice (0.1 to 0.6 and 1 to 5 times the maximum recommended human dose [MRHD] of 200 mg/day on a mg/m<sup>2</sup> basis, respectively). In the rat study, there was no evidence of an increased incidence of tumors compared to controls. In male mice, there was no increase in incidence of tumors relative to controls. In female mice, there were doserelated increases in the incidences of pituitary gland adenoma and carcinoma, and mammary gland adenocarcinoma at all doses tested (50 to 200 mg/kg/day or 1 to 5 times the MRHD on a mg/m<sup>2</sup> basis). Proliferative changes in the pituitary and mammary glands of rodents have been observed following chronic administration of other antipsychotic agents and are considered to be prolactin-mediated. Increases in serum prolactin were observed in a 1-month dietary study in female, but not male, mice at 100 and 200 mg/kg/day (or 2.5 and 5 times the MRHD on a mg/m2 basis). Ziprasidone had no effect on serum prolactin in rats in a 5-week dietary study at the doses that were used in the carcinogenicity study. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents

reproducible mutagenic response in the Ame strain of S. typhimurium in the absence of h vation. Positive results were obtained in both vation. Positive results were obtained in both mammalian cell gene mutation assay and the h mammalian cell gene human lymphocyte in human lymphocyte Impairment of Fertility-Ziprasidone was showed Impairment of Ferunty - sprague-Dawley rats in the time to copulation in optage and in the and early embryonic development studies at do and early embryonic development or at done 160 mg/kg/day (0.5 to 8 times the MRHD of 200 bu 160 mg/kg/day (0.5 to o times the duced at 160 hy mg/m<sup>2</sup> basis). Fertility rate was reduced at 160 hy mg/m<sup>2</sup> basis). There is the  $mg/m^2$  basis). Fertinty rate was to be the 100 mg times the MRHD on a  $mg/m^2$  basis). There was as fertility at 40 mg/kg/day (2 times the MRHD for a fartility appeared to be the second fertility at 40 mg/kg/day to support to be in the basis). The effect on fertility appeared to be in the interview of the basis. basis). The effect on fertinity appearance as the in  $10^{4}$  m since fertility was not impaired when males given is kg/day (8 times the MRHD on a mg/m<sup>2</sup> basis) were kg/day (8 times the females. In a 6-month study in kg/day (8 times the MRHD on a 6-month study in  $m_{\rm eff}$ with untreated females. In a 6-month study in  $m_{\rm eff}$ with untreated females. In a o-month source in ma given 200 mg/kg/day (10 times the MRHD on a mg/kg/day (10 times the MRHD on a mg/kg/day (10 times the mg/kg/day (10 times th given 200 mg/kg/nay (10 innes in a hg/h) there were no treatment-related findings observed

And a state into a state of a sta

milet

the pr

sual

ther

ampa tation

18.1

physic

ident

in th st or

41 63

Tabl

Body

Body

A

Ac

Corc Tt P Digi N C L L I MI

1 1 1

testes. Pregnancy — Pregnancy Category C—In animal temperature developmental toxicity is Pregnancy — Pregnancy Gategory animal a ziprasidone demonstrated developmental toxicity be ziprasidone demonstrated de terres similar to hung possible teratogenic elieus activity and an antiparte apeutic doses. When ziprasidone was administered a second of organome. apeutic doses, when ziprastore of or organogenesis increased incidence of fetal structural abnormatical increased incidence of fetal structural abnormatical increased incidence and other cardiovascula. increased incidence of letal structure union malities tricular septal defects and other cardiovascular male tions and kidney alterations) was observed at a dos tions and kidney alterations/ was associated at a dom 30 mg/kg/day (3 times the MRHD of 200 mg/day on a new association of a suggest that the suggest the suggest the suggest that the suggest 30 mg/kg/day (3 times the written to suggest that these days have basis). There was no evidence to suggest that these days have been appendix to maternal to be a suggest that these days have been appendix to maternal to be appendix to maternal to be appendix to basis). There was no evidence to support that diese de opmental effects were secondary to maternal tonicity to the second opmental effects were secondary in mg/kg/day (equivale developmental no-effect dose was 10 mg/kg/day (equivale to the MRHD on a mg/m<sup>2</sup> basis). In rats, embryofital to to the MRHD on a mg/m beam of the select of ossification of 10 to 160 motors was observed following administration of 10 to 160 motors was observed following administration of a mg/m basis data of the MRHD on a mg/m basis data of t was observed following automation and a 10 to 160 mb day (0.5 to 8 times the MRHD on a mg/m<sup>2</sup> basis) during the second day and day (0.5 to 8 times the initial station, but there was no station of 40 and 160 wes no station of 40 and 160 wes no station of 40 and 160 west no station of ganogenesis or throughout gestation, but there was noted dence of teratogenicity. Doses of 40 and 160 mg/kg/day and 8 times the MRHD on a mg/m<sup>2</sup> basis) were associated with maternal toxicity. The developmental no effect of the development of the mg/kg/day of the mg/kg/day. was 5 mg/kg/day (0.2 times the MRHD on a mg/m<sup>2</sup> bar There was an increase in the number of pups born deal and There was an increase in the number of paps non-dead as a decrease in postnatal survival through the first 4 days lactation among the offspring of female rats treated dur-gestation and lactation with doses of 10 mg/kg/day of times the MRHD on a mg/m<sup>2</sup> basis) or greater. Offspring da velopmental delays and neurobehavioral functional impair ment were observed at doses of 5 mg/kg/day (0.2 times the MRHD on a mg/m<sup>2</sup> basis) or greater. A no-effect level not established for these effects. There are no adequate and well-controlled studies in pre-

nant women. Ziprasidone should be used during pregnano only if the potential benefit justifies the potential risk to the fetus. rine (

Labor and Delivery-The effect of ziprasidone on labor and delivery in humans is unknown.

Nursing Mothers-It is not known whether, and if so is what amount, ziprasidone or its metabolites are excreted in human milk. It is recommended that women receiving ziprasidone should not breast feed.

Pediatric Use-The safety and effectiveness of ziprasidone in pediatric patients have not been established. Geriatric Use-Of the approximately 4500 patients treated with ziprasidone in clinical studies, 2.4% (109) were 65 years of age or over. In general, there was no indication of any different tolerability of ziprasidone or for reduced clear ance of ziprasidone in the elderly compared to younge adults. Nevertheless, the presence of multiple factors that might increase the pharmacodynamic response b ziprasidone, or cause poorer tolerance or orthostasis, should lead to consideration of a lower starting dose, slower titra tion, and careful monitoring during the initial dosing period for some elderly patients.

ADVERSE REACTIONS The premarketing development program for ord ziprasidone included over 5400 patients and/or normal subjects exposed to one or more doses of ziprasidone. Of the 5400 subjects, over 4500 were patients who participated or multiple-dose effectiveness trials, and their experience or responded to approximately 1733 patient years. The conditions and duration of tracks tions and duration of treatment with ziprasidone includes open-label and double-blind studies, inpatient and outpu-tient studies and elements. tient studies, and short-term and longer-term exposure. The premarketing development of longer-term exposure. premarketing development program for intramuse ziprasidone included 570 patients and/or normal subject who received one or more injections of ziprasidone. Over all of these subjects participated in trials involving the admin istration of multiple down

Adverse events during exposure were obtained by collecting voluntarily reported adverse experiences, as well as result of physical examinations, vital signs, weights, laboratori analyses, ECGs and new times the second s analyses, ECGs, and results of ophthalmologic examinations. Adverse experiences tions. Adverse experiences were recorded by clinical conquently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse while without first grouping similar to a similar tigators using terminology of their own choosing without first grouping similar types of events into a small number of standardized event categories. In the tables at tabulations that follows the standard to the standar Mutagenesis –Ziprasidone was tested in the Arges bacterial mouse lymphoma assay, the *in vitro* chromosomal aberraportion of individuals who experienced, at least once a

considered treatment emergent if it occurred for ime or worsened while receiving therapy following evaluation.

in olivo

n to int two for

oses of mg/di mg/kg/ no et

on a

1 the f

ven 160

Were n

n male

ng/m<sup>2</sup> here rved in Ua

nal studies y, includies

uman then red to prov

enesia at lities (vite

malforne

a dose

equivalent fetal teris

sification

60 mgA

during c

'as no evi /kg/day (1

issociate ffect dos

1<sup>2</sup> basis) dead and

4 days of ad durin

/day (0.)

pring de

d impair

imes the

evel was

in pres-

egnand

sk to the

abor and

if so in

reted in

aceiving

asidone

treated

vere 65 ation of

d clear

ounger

factors

nse to

should

rititra-

period

orol

sub

these

ted in

e cor ondi-ludeo

The

jects . 925 min.

ting

ults

ins. res. ate of a ler of a ler

Findings Observed in Short-Term, Placebo-

during findings are based on a pool of two 6-week, 4-week placebo-controlled total was administered in doses ranging from 10 to

Events Associated with Discontinuation of Treatshort-Term, Placebo-Controlled Trials of Oral

outpately 4.1% (29/702) of ziprasidone-treated paidone short-term, placebo-controlled studies discontin-mathematical discontin- $m_{p,0}^{at}$  (6/273) on placebo. The most second with (6/273) on placebo. The most common event aswith dropout was rash, including 7 dropouts for and what are used rated, including / dropouts for

a mong ziprastone patients (1// a mong ziprastone patients (1// patients (see PRECAUTIONS). Events Occurring at an Incidence of 1% or More Torasidone-Treated Patients in Short-Term, Oral, one controlled Trials

induced to the incidence, rounded to the nearest during acute therapy (up to 6 weeks) in predomithe schizophrenic patients, including only those why hat occurred in 1% or more of patients treated with the schild of which the inside untir. sidone and for which the incidence in patients treated with prasidone was greater than the incidence in placebosted patients. nor Ok in seet

m a mg/m lease devel xicity Th prescriber should be aware that these figures cannot be to predict the incidence of side effects in the course of medical practice where patient characteristics and at factors differ from those which prevailed in the trial trials. Similarly, the cited frequencies cannot be apared with figures obtained from other clinical investineeds involving different treatments, uses, and investiga-The cited figures, however, do provide the prescribing idan with some basis for estimating the relative condution of drug and non-drug factors to the side effect inlence rate in the population studied.

these studies, the most commonly observed adverse usts associated with the use of ziprasidone (incidence of (segreater) and observed at a rate on ziprasidone at least nes that of placebo were somnolence (14%), extrapyramialsyndrome (5%), and respiratory disorder (8%).

table 1. Treatment-Emergent Adverse Event Incidence In Short-Term Oral Placebo-Controlled Trials

in advertación de advertación de	Percentage of Patients Reporting Event	
hir System/Adverse Event	Ziprasidone (N=702)	Placebo (N=273)
Body as a Whole	a minufitension nain nd bligada	approx post
Asthenia	n ne 15 o char	tor a line populo 8 that
Acidental Injury	tos nouclos f de la sta jun 0	0 - 2 (di)
Cirdiovascular	n El molanto h	or nocurio nocurificato
Tachycardia	2	integn <b>1</b> 1111 mitr að linna
Postural Hypotension	o lun len 250	ord 0
Digistive Detendence blace	u suatena pusi	ienoral) Melani
Nausea	10 10 10	701 17 00
Constipation	9	80803
Dyspepsin	Band Banan	7 5
Diarrhea (doctalit) months and	a waaab g mer k	all all a
Dry Mouth	4	2
Anorexia	2	1
Musculoskeletal	thad shiring	elette itt
Myalgia Nervous	angur <b>h</b>	0
Somnolence	14	7
Akathisia	8	8'7
Disziness	8	6
Edrapyramidal Syndrome	5	1
Jatonia	4	2
Hypertonia	3	2
Respiratory Disorder*	ase 2:11	-cv-90

Cough Increased	<b>3</b>	1	
Skin and Appendages	oral controls	- स्वाताल्डा - क्रांटी जिल् सीर जानि	
Rash	06.01.466.091	δ. γ	
Fungal Dermatitis	2	1 1	
Special Senses	Julio Same	-	
Abnormal Vision	3	2	

\*Cold symptoms and upper respiratory infection account for >90% of investigator terms pointing to "respiratory disorder".

Explorations for interactions on the basis of gender did not reveal any clinically meaningful differences in the adverse event occurrence on the basis of this demographic factor. Dose Dependency of Adverse Events in Short-Term, Placebo-Controlled Trials

An analysis for dose response in this 4-study pool revealed an apparent relation of adverse event to dose for the following events: asthenia, postural hypotension, anorexia, dry mouth, increased salivation, arthralgia, anxiety, dizziness, dystonia, hypertonia, somnolence, tremor, rhinitis, rash, and abnormal vision.

Extrapyramidal Symptoms (EPS)-The incidence of reported EPS for ziprasidone-treated patients in the shortterm, placebo-controlled trials was 5% vs. 1% for placebo. Objectively collected data from those trials on the Simpson Angus Rating Scale (for EPS) and the Barnes Akathisia Scale (for akathisia) did not generally show a difference between ziprasidone and placebo.

Vital Sign Changes-Ziprasidone is associated with orthostatic hypotension (see PRECAUTIONS).

Weight Gain-The proportions of patients meeting a weight gain criterion of  $\geq$ 7% of body weight were compared in a pool of four 4- and 6-week placebo-controlled clinical trials, revealing a statistically significantly greater incidence of weight gain for ziprasidone (10%) compared to placebo (4%). A median weight gain of 0.5 kg was observed in ziprasidone patients compared to no median weight change in placebo patients. In this set of clinical trials, weight gain was reported as an adverse event in 0.4% and 0.4% of ziprasidone and placebo patients, respectively. During long-term therapy with ziprasidone, a categorization of patients at baseline on the basis of body mass index (BMI) revealed the greatest mean weight gain and highest incidence of clinically significant weight gain (>7% of body weight) in patients with low BMI (<23) compared to normal (23-27) or overweight patients (>27). There was a mean weight gain of 1.4 kg for those patients with a "low" baseline BMI, no mean change for patients with a "normal" BMI, and a 1.3 kg mean weight loss for patients who entered the program with a "high" BMI.

ECG Changes-Ziprasidone is associated with an increase in the QTc interval (see WARNINGS). Ziprasidone was associated with a mean increase in heart rate of 1.4 beats per minute compared to a 0.2 beats per minute decrease among placebo patients.

Other Adverse Events Observed During the Premarketing Evaluation of Oral Ziprasidone

Following is a list of COSTART terms that reflect treatment-emergent adverse events as defined in the introduction to the ADVERSE REACTIONS section reported by patients treated with ziprasidone at multiple doses >4 mg/ day within the database of 3834 patients. All reported events are included except those already listed in Table 1 or elsewhere in labeling, those event terms that were so general as to be uninformative, events reported only once and that did not have a substantial probability of being acutely life-threatening, events that are part of the illness being treated or are otherwise common as background events, and events considered unlikely to be drug-related. It is important to emphasize that, although the events reported occurred during treatment with ziprasidone, they were not necessarily caused by it.

Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring in at least 1/100 patients (only those not already listed in the tabulated results from placebo-controlled trials appear in this listing); infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients.

Body as a Whole: Frequent: abdominal pain, flu syndrome, fever, accidental fall, face edema, chills, photosensitivity reaction, flank pain, hypothermia, motor vehicle accident.

Cardiovascular System: Frequent: hypertension; Infrequent: bradycardia, angina pectoris, atrial fibrillation; Rare: first degree AV block, bundle branch block, phlebitis, pulmonary embolus, cardiomegaly, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, myocarditis, thrombophlebitis.

Digestive System: Frequent: vomiting; Infrequent: rectal 36 hemoritage, deupingria, tongria edema; Rare, gum hemor 36 ringe, mundler, tech impletion, gamana ghutang traaspol tidase increased, hematemesis, cholestatic jaundice, hepati-

metena Endocrine: Rare: hypothyroidism, hyperthyroidism, thyroiditis.

Hemic and Lymphatic System: Infrequent: anemia, ecchymosis, leukocytosis, leukopenia, eosinophilia, lymphadenopathy; Rare: thrombocytopenia, hypochromic anemia, lymphocytosis, monocytosis, basophilia, lymphedema, polycythemia, thrombocythemia.

Metabolic and Nutritional Disorders: Infrequent: thirst, transaminase increased, peripheral edema, hyperglycemia, creatine phosphokinase increased, alkaline phosphatase increased, hypercholesteremia, dehydration, lactic dehydrogenase increased, albuminuria, hypokalemia; Rare: BUN increased, creatinine increased, hyperlipemia, hypocholesteremia, hyperkalemia, hypochloremia, hypoglycemia, hy-ponatremia, hypoproteinemia, glucose tolerance decreased, gout, hyperchloremia, hyperuricemia, hypocalcemia, hypoglycemic reaction, hypomagnesemia, ketosis, respiratory alkalosis.

Musculoskeletal System: Infrequent: tenosynovitis; Rare: myopathy.

Nervous System: Frequent: agitation, tremor, dyskinesia, hostility, paresthesia, confusion, vertigo, hypokinesia, hyperkinesia, abnormal gait, oculogyric crisis, hypesthesia, ataxia, amnesia, cogwheel rigidity, delirium, hypotonia, akinesia, dysarthria, withdrawal syndrome, buccoglossal syndrome, choreoathetosis, diplopia, incoordination, neuropathy; Rare: myoclonus, nystagmus, torticollis, circumoral paresthesia, opisthotonos, reflexes increased, trismus. Respiratory System: Frequent: dyspnea; Infrequent: pneu-

monia, epistaxis; Rare: hemoptysis, laryngismus. Skin and Appendages: Infrequent: maculopapular rash, urticaria, alopecia, eczema, exfoliative dermatitis, contact dermatitis, vesiculobullous rash.

Special Senses: Infrequent: conjunctivitis, dry eyes, tinnitus, blepharitis, cataract, photophobia; Rare: eye hemorrhage, visual field defect, keratitis, keratoconjunctivitis.

Urogenital System: Infrequent: impotence, abnormal ejaculation, amenorrhea, hematuria, menorrhagia, female lactation, polyuria, urinary retention, metrorrhagia, male sexual dysfunction, anorgasmia, glycosuria; Rare: gynecomastia, vaginal hemorrhage, nocturia, oliguria, female sexual dysfunction, uterine hemorrhage.

Adverse Findings Observed in Trials of Intramuscular Ziprasidone

Adverse Events Occurring at an Incidence of 1% or More Among Ziprasidone-Treated Patients in Short-Term Trials of Intramuscular Ziprasidone

Table 2 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse events that occurred during acute therapy with intramuscular ziprasidone in 1% or more of patients.

In these studies, the most commonly observed adverse events associated with the use of intramuscular ziprasidone (incidence of 5% or greater) and observed at a rate on intramuscular ziprasidone (in the higher dose groups) at least twice that of the lowest intramuscular ziprasidone group were headache (13%), nausea (12%), and somnolence (20%). [See table 2 at bottom of next page] Str. Moulds

DRUG ABUSE AND DEPENDENCE

Controlled Substance Class-Ziprasidone is not a controlled substance.

Physical and Psychological Dependence-Ziprasidone has not been systematically studied, in animals or humans, for its potential for abuse, tolerance, or physical dependence. While the clinical trials did not reveal any tendency for drug-seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which ziprasidone will be misused, diverted, and/or abused once marketed. Consequently, patients should be evaluated carefully for a history of drug abuse, and such patients should be observed closely for signs of ziprasidone misuse or abuse (e.g., development of tolerance, increases in dose, drug-seeking behavior).

#### OVERDOSAGE

Human Experience-In premarketing trials involving more than 5400 patients and/or normal subjects, accidental or intentional overdosage of oral ziprasidone was documented in 10 patients, All of these patients survived without sequelae. In the patient taking the largest confirmed amount, 3240 mg, the only symptoms reported were minimal sedation, slurring of speech, and transitory hypertension (200/

Management of Overdosage-In case of acute overdosage, establish and maintain an airway and ensure adequate oxvgenation and ventilation. Intravenous access should be established and gastric lavage (after intubation, if patient is unconscious) and administration of activated charcoal together with a laxative should be considered. The possibility of obtundation, seizure, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.

Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects that might be additive to those of ziprasidone. Hypotension and circulatory collapse should be treated with appropriate measures such as intravenous fluids. If Document 171-6

Continued on next page

sympathomimetic agents are used for vascular support, epinephrine and dopamine should not be used, since beta stimulation combined with  $\alpha_1$  antagonism associated with ziprasidone may worsen hypotension. Similarly, it is reasonable to expect that the alpha-adrenergic-blocking properties of bretylium might be additive to those of ziprasidone, resulting in problematic hypotension.

cinc antidote to ziprasidone, and it is not dialyzable. The possibility of multiple drug involvement should be considered. Close medical supervision and monitoring should continue until the patient recovers.

### DOSAGE AND ADMINISTRATION

When deciding among the alternative treatments available for schizophrenia, the prescriber should consider the finding

The second	Per Per	centage of Patients Reporti	ng Friend
Body System/Adverse Event	Ziprasidone 2 mg	the second se	Ziprasidone 20 m
Body as a Whole	(N=92)	(N=63)	(N=41)
Headache	ad and a		
		13	5 <sup>-12</sup> Call 115 - 5
Injection Site Pain	9	8	with million <b>7</b> 00 adds
Asthenia		0	head and the second
Abdominal Pain	0	2	r 0
Flu Syndrome		0	. 0
	figs    program 1	0	0
	Pro 1 Laters I Prod	a the special series	Supersona a
- obtained any potension	en (	0	1 49 - ± 5
Hyperténsion	2	0	1 001 ptpl 0
Bradycardia	0	0	2
Vasodilation	6 3 3 - 0 - 1 1	0	C III OF THE OF THE
Digestive	and the second	4) ki = 1-lietti es altonia (	9.27 (0.65) (1995) 0.17 (1995) (1995)
Nausea the sector of the sector and	Par di perintensi <b>4</b> di men	n do e Calang Kali a Han	the first of the sectores
Rectal Hemorrhage	intel smadbé o potrane	a utilope of <b>0</b> or shallow	1 116 1
Diarrhea	the second s	30.700.85 State	il no hong <b>2</b> is aligned The state of a
Vomiting	2 1 114g 0	Transfer of the second states	Politica da Rei 2 il fabra E (Honizia) galerada di
Dyspepsia	TV TI OF DEPEND	<ul> <li>sum a bio constante</li> <li>sum a bio constante</li> <li>sum a bio constante</li> </ul>	an another of the stand goal of
Anorexia		dian - more burgering	file of the least
Constipation -	1 million 1 1 1 1 1	the state of the second state	riukow dino <b>O</b> ranika zlis <u>dinar</u> i
Tooth Disorder	H	THE CHARGE STOLLERS	200 september 2 eligitation
Dry Mouth	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		<b>0</b>
Nervous III in the standard condition of the standard stand	n an annea an	0 Prove the stress stress	0
Dizziness to N- terreturneques to application	and the second se	Internet'S / Standard	and Swinslaw of P not a
Aprioto	and the second s	r and the second s	10
The subset of the second s	phillippi ci 2 phillippi	with which perform to when the	nincut a par <b>o</b> nine : Mire - Astropola El Anno
	i filling worth 3.	stand the state of the state of the	of S land be initiation
Somnolence	8	8 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	20
Akathisia	The Attraction Of the Attraction	the data a wat to	the her of the loss
Agitation	a tu an 2	2 1- of an	ta leann w <mark>o</mark> san atraog
Extrapyramidal Syndrome	2	0	defident of an or Man
Hypertonia	HI WHILE I	de l'El 10 er era Loft er	orde une ontpress
Cogwheel Rigidity	27 Billing and 1 Billing a	Scherife (0 should apply if	na levento de la composición de la comp
Paresthesia	0	an in the 2 would be a fear	a toti 0 a trans
Personality Disorder	- in and 0	2	0
Psychosis	sangonara 1	0	0
Speech Disorder	0	2	0
espiratory			
Rhinitis	1	0	
in and Appendages		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	<ul> <li>Monthlase et (1)</li> <li>Provolution</li> </ul>
Furunculosis	0	2	a setting to provide the
Sweating	0	0	0
ogenital		the same with the second se	2.
Dysmenorrhea	the state of the s		it quits its in a si
Priapism Occor 0.11	0	2	

WARNINGS). Initial Treatment GEODON<sup>®</sup> Capsules should be administered

daily dose of 20 mg BID with food. In some pa dosage may subsequently be adjusted on the b vidual clinical status up to 80 mg BID. Dosage if indicated, should generally occur at interva than 2 days, as steady-state is achieved within In order to ensure use of the lowest effective dog more to ensure use of the lowest enterty of the patients should be observed for improvement weeks before upward dosage adjustment. Efficacy in schizophrenia was demonstrated in a

anupsychotic

not ac aninist apras apras d by nECD.

pac

single 1

storage dored at

dry fr GEODOI

cht, for

lays refi

Rx only 02003 Pi

dribul

prizer Ro

AB-027

Revised -

GLUCC

Iglipizidi Extende

For Oral

DESCR Glipizide

fonylure: The Che

(ip-[2-(5-Çorea. T

br weigl

H<sub>3</sub>C-

Glipizide insolu NaOH;

GITS. G

(em) is for oral

clipizide

lhert ing tions are

chlaride

col, Opa

white ()

S-1-810

System GLUCO

pearance

samotica ble men

"Iclive" Hising

compone neable

"ater fr te inc Tug hay tablet E GL a provi

ta trair traintes Entende

stotic al flui Cont ar ols o uning LINI

be par be par talls in bay pli

of 20 to 100 mg BID in short-term, placebo-cont. of 20 to 100 mg BLD in short-term, places cannot cal trials. There were trends toward dose respon the range of 20 to 80 mg BID, but results were tent. An increase to a dose greater than 80 mg generally recommended. The safety of doses abo BID has not been systematically evaluated in clin **Maintenance Treatment** While there is no body of evidence available to

question of how long a patient treated with hould remain on it, systematic evaluation of has shown that its efficacy in schizophrenia is for periods of up to 52 weeks at a dose of 20 to (see CLINICAL PHARMACOLOGY). No addition fit was demonstrated for doses above 20 mg Bib, p should be periodically reassessed to determine the maintenance treatment. Intramuscular Administration

Intramuscular Administration The recommended dose is 10 to 20 mg administered a quired up to a maximum dose of 40 mg per day bo quired up to a maximum cose of the hours; dose of 20, 10 mg may be administered every two hours; dose of 20, 10 mg may be administered every four hours up to a maximum may be administered every four hours up to a maximum may be administered every four future of a maximum 40 mg/day. Intramuscular administration of ziprasidone 40 mg/day. Intramuscum dammas has not been studied, more than three consecutive days has not been studied. If long-term therapy is indicated, oral ziprasidone by chloride capsules should replace the intramuscular ada istration as soon as possible.

istration as soon as possible. Since there is no experience regarding the safety of adm istering ziprasidone intramuscular to schizophr patients already taking oral ziprasidone, the practice of administration is not recommended.

Dosing in Special Populations Oral: Dosage adjustments are generally not requi on the basis of age, gender, race, or renal or hepe impairment.

Intramuscular: Ziprasidone intramuscular has not be systematically evaluated in elderly patients or in patie with hepatic or renal impairment. As the cyclodextrin eso ient is cleared by renal filtration, ziprasidone intramuse should be administered with caution to patients with paired renal function. Dosing adjustments are not requon the basis of gender or race.

Preparation for Administration GEODON® for Injection (ziprasidone mesylate) should us be administered by intramuscular injection. Single-dows als require reconstitution prior to administration; any used portion should be discarded.

Add 1.2 mL of Sterile Water for Injection to the vial as shake vigorously until all the drug is dissolved. Each mL reconstituted solution contains 20 mg ziprasidone. To a minister a 10 mg dose, draw up 0.5 mL of the reconstitute solution. To administer a 20 mg dose, draw up 1.0 mL dt reconstituted solution. Since no preservative or backet static agent is present in this product, aseptic technique must be used in preparation of the final solution. This edicinal product must not be mixed with other medicas products or solvents other than Sterile Water for Injection Parenteral drug products should be inspected visually in particulate matter and discoloration prior to administra tion, whenever solution and container permit. HOW SUPPLIED

GEODON<sup>®</sup> Capsules are differentiated by capsule colorisa and are imprinted in black ink with "Pfizer" and a unit number. GEODON Capsules are supplied for oral admini-tratical and a supplied for oral administration of the supplied for oral administration of the supplied for oral administration of the supplicit for oral administration of t tration in 20 mg (blue/blue), 40 mg (blue/blue), 60 mg (blue), 60 mg (b (white/white), and 80 mg (blue/white) capsules are supplied in the following strengths and partial configurations:

14 11-11	GEODO	ON <sup>®</sup> Capsules
Package Configuration	Capsule Strength (mg)	NDC Code
Bottles of 60	20	NDC-0049-3960-60
Bottles of 60	40	NDC-0049-3970-60
Bottles of 60	60	NDC-0049-3980-60
Bottles of 60	80	NDC-0049-3990.60
Unit dose/80	20	NDC-0049-3960-41
Unit dose/80	40	NDC-0049-3970-41
Unit dose/80	60	NDC-0049-3980-41
Docume	nt 1/71-	GNDC-0049-3990-41

injection is available in a single dose vial as for hydre (20 mg ziprasidone/mL when reconstito label instructions—see Preparation for for intramuscular administration. Each mL mesylate for injection (when reconstituted) polorless to pale pink solution that contains 20 mg olore and 4.7 mg of methanesulfonic acid solubidone ng of sulfobutylether β-cyclodextrin sodium

stered ;

n the

nterval within i ive dos

rement for

ted in a dom bo-controller

le response

iscular adm

fety of ada

schizophres

practice of a

tramuscu

its with in

not require

should only

gle-dose n

on; any us

ie vial and

Each mLd

ne. To ad

constituted

mL of the

bacterio

technique

This me

medicinal

Injection

sually for

ministra-

color/size

unique

adminis

nckage

nprint

396

397

198

99

17

60 mg

They

ome

01	EODON <sup>®</sup> for Injec	tion
G	Concentration	NDC Code
ckage	20 mg/mL	NDC-0049-3920-83
Use Vials	20 mg/mL	MDC-0049-3920-83

<sup>3</sup> Teapone voi s were bat on 80 hg BID at ses above ho 1 in clinical tra and Handling-GEODON<sup>®</sup> for Injection should be at controlled room temperature, 15°-30°C (59°-86°F) form. Protect from light, Following reconstitution, form injection can be stored, when protected from to for the 24 hours at 15°-30°C (59°-86°F) or up to 7 ble to answer don to a stored, when protected from r up to 24 hours at 15\*-30°C (59\*-86°F) or up to 7 prigerated, 2°-8°C (36°-46°F).

ziprasidone en studied. maters bireaulid - approve last asidone hyd:

anti-tise-Infinity Bucotrol XL® ended Release Tablets Body as a whole while homosoli bas gillatimanda itan swapi

ISCRIPTION OF WORK DEC. PRESS, MINISTER PRESS, ide is an oral blood-glucose-lowering drug of the sulnot require breaclass, beridagine immiteder l or hepata Chemical Abstracts name of glipizide is 1-cyclohexyl-3p.(5-methylpyrazinecarboxamido)ethyl] phenyl]sulfonyas not been The molecular formula is C<sub>21</sub>H<sub>27</sub>N<sub>5</sub>O<sub>4</sub>S; the molecu-eight is 445.55; the structural formula is shown below: r in patient extrin exce

dimental-distance (1) ΗĂ -SO2NHCONH -CONHCH2CH2- $(\bigcirc$ fig au built line as a 90 limiteducousing localization were not from he burying, unibashi femilashi

While is a whitish, odorless powder with a pKa of 5.9. It issoluble in water and alcohols, but soluble in 0.1 N 20H, it is freely soluble in dimethylformamide. UCOTROL XL<sup>®</sup> is a registered trademark for glipizide 178 Glipizide GITS (Gastrointestinal Therapeutic Sys-(b) is formulated as a once-a-day controlled release tablet wal use and is designed to deliver 2.5, 5, or 10 mg of

att ingredients in the 2.5 mg, 5 mg and 10 mg formulaare: polyethylene oxide, magnesium stearate, sodium stde, red ferric oxide, cellulose acetate, polyethylene gly-Dada hus OVIS 20021/25 mg tableta) (Daday Opadry® blue (OY-LS-20921)(2.5 mg tablets), Opadry the (YS-2-7063)(5 mg and 10 mg tablet) and black ink \$1.8106).

m Components and Performance ACOTROL XL Extended Release Tablet is similar in apterance to a conventional tablet. It consists, however, of an <sup>totically</sup> active drug core surrounded by a semipermeamembrane. The core itself is divided into two layers: an "live" layer containing the drug, and a "push" layer conusing pharmacologically inert (but osmotically active) nents. The membrane surrounding the tablet is perwhere the two other is a surround on the section of "a increases in the osmotic layer and "pushes" against the by layer, resulting in the release of drug through a small, et drilled orifice in the membrane on the drug side of the

LUCOTROL XL Extended Release Tablet is designed Rovide a controlled rate of delivery of glipizide into the and a controlled rate of desired on the of the or gasantestinal lumen which is independent of price and antestinal motility. The function of the GLUCOTROL XL unded Release Tablet depends upon the existence of an and Release Tablet depends upon an and the bi-layer core d Rud in the GI tract. Drug delivery is essentially consurvey in the GI tract. Drug denvery is the constant, and the long as the osmotic gradient remains constant, and the Bradually falls to zero. The biologically inert compo-tion of transit and are and a final state of the tablet remain intact during of table of the tablet remain intact during GI transit and are

# INICAL PHARMACOLOGY

Chanism of Action: Glipizide appears to lower blood Realism of Action: Glipizide appears to lower starting acutely by stimulating the release of insulin from

crease in insulin sensitivity and a decrease in hepatic glucose production. However, the mechanism by which glipizide lowers blood glucose during long-term administration has not been clearly established. Stimulation of insulin secretion by glipizide in response to a meal is of major importance. The insulinotropic response to a meal is enhanced with GLUCOTROL XL administration in diabetic patients. The postprandial insulin and C-peptide responses continue to be enhanced after at least 6 months of treatment. In 2 randomized, double-blind, dose-response studies comprising a total of 347 patients, there was no significant increase in fasting insulin in all GLUCOTROL XL-treated patients combined compared to placebo, although minor elevations were observed at some doses. There was no increase in fasting insulin over the long term.

Some patients fail to respond initially, or gradually lose their responsiveness to sulfonylurea drugs, including glipizide. Alternatively, glipizide may be effective in some patients who have not responded or have ceased to respond to other sulfonylureas.

#### **Effects on Blood Glucose** The effectiveness of GLUCOTROL XL Extended Release Tablets in type 2 diabetes at doses from 5-60 mg once daily has been evaluated in 4 therapeutic clinical trials each with long-term open extensions involving a total of 598 patients. Once daily administration of 5, 10 and 20 mg produced statistically significant reductions from placebo in hemoglobin A1C, fasting plasma glucose and postprandial glucose in patients with mild to severe type 2 diabetes. In a pooled analysis of the patients treated with 5 mg and 20 mg, the rela-tionship between dose and GLUCOTROL XL's effect of reducing hemoglobin A1C was not established. However, in the case of fasting plasma glucose patients treated with 20 mg had a statistically significant reduction of fasting plasma glucose compared to the 5 mg-treated group. The reductions in hemoglobin $A_{1C}$ and fasting plasma glu-cose were similar in younger and older patients. Efficacy of

GLUCOTROL XL was not affected by gender, race or weight (as assessed by body mass index). In long term extension trials, efficacy of GLUCOTROL XL was maintained in 81% of patients for up to 12 months.

In an open, two-way crossover study 132 patients were randomly assigned to either GLUCOTROL XL or Glucotrol® for 8 weeks and then crossed over to the other drug for an additional 8 weeks. GLUCOTROL XL administration resulted in significantly lower fasting plasma glucose levels and equivalent hemoglobin  $A_{1C}$  levels, as compared to Glucotrol. Other Effects: It has been shown that GLUCOTROL XL therapy is effective in controlling blood glucose without deleterious changes in the plasma lipoprotein profiles of patients treated for type 2 diabetes. In a placebo-controlled, crossover study in normal volunteers, glipizide had no antidiuretic activity; and, in fact, led

to a slight increase in free water clearance. Pharmacokinetics and Metabolism: Glipizide is rapidly and completely absorbed following oral administration in an immediate release dosage form. The absolute bioavailability of glipizide was 100% after single oral doses in patients with type 2 diabetes: Beginning 2 to 3 hours after administration of GLUCOTROL XL Extended Release Tablets, plasma drug concentrations gradually rise reaching maximum concentrations within 6 to 12 hours after dosing. With subsequent once daily dosing of GLUCOTROL XL Extended Release Tablets, effective plasma glipizide concentrations are maintained throughout the 24 hour dosing interval with less peak to trough fluctuation than that observed with twice daily dosing of immediate release glipizide. The mean relative bioavailability of glipizide in 21 males with type 2 diabetes after administration of 20 mg GLUCOTROL XL Extended Release Tablets, compared to immediate release Glucotrol (10 mg given twice daily), was 90% at steadystate. Steady-state plasma concentrations were achieved by at least the fifth day of dosing with GLUCOTROL XL Extended Release Tablets in 21 males with type 2 diabetes and patients younger than 65 years. Approximately 1 to 2 days longer were required to reach steady-state in 24 elderly (≥65 years) males and females with type 2 diabetes. No accumulation of drug was observed in patients with type 2 di-abetes during chronic dosing with GLUCOTROL XL Extended Release Tablets. Administration of GLUCOTROL XL with food has no effect on the 2 to 3 hour lag time in drug absorption. In a single dose, food effect study in 21 healthy male subjects, the administration of GLUCOTROL XL immediately before a high fat breakfast resulted in a 40% increase in the glipizide mean Cmax value, which was significant, but the effect on the AUC was not significant. There was no change in glucose response between the fed and fasting state. Markedly reduced GI retention times of the GLUCOTROL XL tablets over prolonged periods (e.g., short bowel syndrome) may influence the pharmacokinetic profile of the drug and potentially result in lower plasma concentrations. In a multiple dose study in 26 males with type 2 diabetes, the pharmacokinetics of glipizide were linear over the dose range of 5 to 60 mg of GLUCOTROL XL in that the plasma drug concentrations increased proportionately with dose. In a single dose study in 24 healthy subjects, four 5 mg, two 10 mg, and one 20 mg GLUCOTROL XL Extended Release Tablets were bioequivalent. In a separate to the pancreatic isle **Beopic 1 alic Ciccol 3 and Bench 1 alic C** 

Glipizide is eliminated primarily by hepatic biotransformation: less than 10% of a dose is excreted as unchanged drug in urine and feces; approximately 90% of a dose is excreted as biotransformation products in urine (80%) and feces (10%). The major metabolites of glipizide are products of aromatic hydroxylation and have no hypoglycemic activity. A minor metabolite which accounts for less than 2% of a dose, an acetylamino-ethyl benzene derivative, is reported to have 1/10 to 1/3 as much hypoglycemic activity as the parent compound. The mean total body clearance of glipizide was approximately 3 liters per hour after single intravenous doses in patients with type 2 diabetes. The mean apparent volume of distribution was approximately 10 liters. Glipizide is 98-99% bound to serum proteins, primarily to albumin. The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes. There were no significant differences in the pharmacokinetics of glipizide after single dose administration to older diabetic subjects compared to younger healthy subjects. There is only limited information regarding the effects of renal impairment on the disposition of glipizide, and no information regarding the effects of hepatic disease. However, since glipizide is highly protein bound and hepatic biotransformation is the predominant route of elimination, the pharmacokinetics and/or pharmacodynamics of glipizide may be altered in patients with renal or hepatic impairment. In mice no glipizide or metabolites were detectable autoradiographically in the brain or spinal cord of males or females, nor in the fetuses of pregnant females. In another study, however, very small amounts of radioactivity were detected in the fetuses of rats given labelled drug.

#### PERCEPTIONS INDICATIONS AND USAGE

GLUCOTROL XL is indicated as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with type 2 diabetes formerly known as noninsulin-dependent diabetes mellitus (NIDDM) or maturityonset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory. GLUCOTROL XL is indicated when diet alone has been unsuccessful in correcting hyperglycemia, but even after the introduction of the drug in the patient's regimen, dietary measures should continue to be considered as important. In 12 week, well-controlled studies there was a maximal average net reduction in hemoglobin A1C of 1.7% in absolute units between placebo-treated and GLUCOTROL XL-treated patients.

In initiating treatment for type 2 diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed, cardiovascular risk factors should be identified, and corrective measures taken where possible.

If this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea should be considered. If additional reduction of symptoms and/or blood glucose is required, the addition of insulin to the treatment regimen should be considered. Use of GLUCOTROL XL must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood-glucose control on diet alone also may be transient, thus requiring only short-term administration of glipizide.

Some patients fail to respond initially or gradually lose their responsiveness to sulfonylurea drugs, including GLUCOTROL XL. In these cases, concomitant use of GLUCOTROL XL with other oral blood-glucose-lowering agents can be considered. Other approaches that can be considered include substitution of GLUCOTROL XL therapy with that of another oral blood-glucose-lowering agent or insulin. GLUCOTROL XL should be discontinued if it no longer contributes to glucose lowering. Judgment of response to therapy should be based on regular clinical and laboratory evaluations. In considering the use of GLUCOTROL XL in asymptomatic patients, it should be recognized that controlling blood glucose in type 2 diabetes has not been definitely established to be effective in preventing the long-term cardiovascular or neural complications of diabetes. However, in insulindependent diabetes mellitus controlling blood glucose has been effective in slowing the progression of diabetic retinopathy, nephropathy, and neuropathy.

#### CONTRAINDICATIONS

Glipizide is contraindicated in patients with:

- 1. Known hypersensitivity to glipizide or any excipients in the GITS tablets.
- 2. Type 1 diabetes, diabetic ketoacidosis, with or without coma. This condition should be treated with insulin. WARNINGS

SPECIAL WARNING ON INCREASED RISK OF CARDIOVAS-CULAR MORTALITY: The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial de-

Document 171-6 Continued on next page